

Virginia Board of Pharmacy

Pharmaceutical Processor & Dispensing Facility Inspection Report
9960 Mayland Drive, Suite 300
Henrico, VA 23233

www.dhp.virginia.gov/pharmacy
Email: pharmbd@dhp.virginia.gov

Main: 804.367.4456
Fax: 804.527.4472

Permit Number:		Facility Type:	
Facility Name:		Inspection Type:	
Address:		Inspection Results:	
City:		Date of Last Inspection:	
State:		Inspection Dates:	
Zip Code:		Inspector Name:	
Designated Health Service Area:		Pharmacist-in-Charge:	
Telephone number:		Pharmacist-in-Charge License Number:	
Toll free number:		Pharmacist-in-Charge Email:	
Fax number:		Pharmacist on Duty / License Number:	
Email address:		Corporate Point of Contact Name and Email:	
Website:		Responsible Party Name:	
		Responsible Party Email:	
Hours of Operation	Is facility open 24/7?		
		Open	Closed
		Start Time: (24-hour format hh:mm)	End Time: (24-hour format hh:mm)
Sunday			
Monday			
Tuesday			
Wednesday			
Thursday			
Friday			
Saturday			
Inspector Notes:			

**Business Licensure Information for State of Residence and Federal
(board of pharmacy, state controlled substance, DEA, FDA, etc.)**

License/Registration Agency	Business Name on License/Registration	License/Registration Type/Number	Expiration Date

Personnel

Personnel present at the time of inspection:

Pharmacists:		Pharmacist:Pharmacy Technician Ratio		
Pharmacy Technicians:		Pharmacy Interns:		Unlicensed Staff:
Responsible Party:				

List all personnel employed by the processor (Attach list if additional space is required):

Position	Name	License Number	Activity	Describe Degree or Experience - Indicate if training completed (Y/N)
Pharmacist-in-Charge				
Responsible Party				

Personnel

Position	Name	License Number	Activity	Describe Degree or Experience - Indicate if training completed	(Y/N)

Permit & Personnel		
P applies to Pharmaceutical Processor. D applies to Dispensing Facility	Result	Notes
	Processor or Dispensing Facility Permit	§54.1-3442.6
PD	No person shall operate a pharmaceutical processor or cannabis dispensing facility without first obtaining a permit from the Board.	
	Every pharmaceutical processor's dispensing area or cannabis dispensing facility shall be under the personal supervision of a licensed pharmacist on the premises of the pharmaceutical processor or cannabis dispensing facility. The pharmaceutical processor shall ensure that security measures are adequate to protect the cannabis from diversion at all times and the pharmacist-in-charge shall have concurrent responsibility for preventing diversion from the dispensing area.	
	Every pharmaceutical processor shall designate a person who shall have oversight of the cultivation and production areas of the pharmaceutical processor and shall provide such information to the Board. The Board shall direct all communications related to enforcement of requirements related to cultivation and production of cannabis products by the pharmaceutical processor to such designated person.	
	Permits shall be displayed in a conspicuous place on the premises of the pharmaceutical processor and cannabis dispensing facility.	
	In addition to other employees authorized by the Board, a pharmaceutical processor may employ individuals who may have less than two years of experience: <ul style="list-style-type: none"> (i) to perform cultivation-related duties under the supervision of an individual who has received a degree in a field related to the cultivation of plants or a certification recognized by the Board or who has at least two years of experience cultivating plants (ii) to perform extraction-related duties under the supervision of an individual who has a degree in chemistry or pharmacology or at least two years of experience extracting chemicals from plants. (iii) to perform duties at the pharmaceutical processor and cannabis dispensing facility upon certification as a pharmacy technician. 	
PD	No person who has been convicted of a felony under the laws of the Commonwealth or another jurisdiction within the last five years shall be employed by or act as an agent of a pharmaceutical processor or cannabis dispensing facility. [§54.1-3342.6]	
	Every pharmaceutical processor and cannabis dispensing facility shall adopt policies for pre-employment drug screening and regular, ongoing, random drug screening of employees.	
	A pharmacist at the pharmaceutical processor's dispensing area and the cannabis dispensing facility shall determine the number of pharmacy interns, pharmacy technicians and pharmacy technician trainees who can be safely and competently supervised at one time; however, no pharmacist shall supervise more than six persons performing the duties of a pharmacy technician at one time in the pharmaceutical processor's dispensing area or cannabis dispensing facility.	

P applies to Pharmaceutical Processor. D applies to Dispensing Facility		Result	Notes
Cannabis Dispensing Facility			18 VAC 110-60-135
D	A cannabis dispensing facility permit shall not be issued to any person to operate from a private dwelling or residence.		
	A cannabis dispensing facility shall not be located within 1000 feet of a school or day care.		
	If the cannabis dispensing facility is not operational within 90 days from the date the permit is issued, the board shall rescind the permit unless an extension is granted for good cause shown.		
	18VAC110-60-135 (H) A cannabis dispensing facility shall be deemed to have commenced operation if they are in receipt of cannabis products from a pharmaceutical processor.		
Processor Permit			18 VAC 110-60-110
PD	No person who has been convicted of a felony under the Code of Virginia or another jurisdiction within the last five years shall have 5% or greater ownership, be employed by, or act as an agent of a pharmaceutical processor. [18 VAC 110-60-110]		
Employee Licenses & Registration			18 VAC 110-60-170
PD	A pharmacist with a current, unrestricted license issued by the board practicing at the location of the address on the pharmaceutical processor or cannabis dispensing facility application shall be in full and actual charge of the dispensing area of the pharmaceutical processor or of a cannabis dispensing facility and shall serve as the pharmacist-in-charge.		
	A pharmacist with a current,unrestricted license issued by the board shall provide personal supervision on the premises of the dispensing area of the pharmaceutical processor or of a cannabis dispensing facility at all times during its hours of operation.		
P	The person who is designated as the responsible party for a pharmaceutical processor shall practice at the location of the address on the pharmaceutical processor application, shall have oversight of the cultivation and production areas, and shall possess:		
	<ol style="list-style-type: none"> 1. A current, unrestricted license as a pharmacist issued by the board; 2. A degree in chemistry, pharmacology, or a field related to the cultivation of plants; 3. A certification recognized by the board; or 4. At least two years of verifiable experience cultivating plants or extracting chemicals from plants. 		
	<p>A person who holds a current, unrestricted registration as a pharmacy technician pursuant to § 54.1-3321 of the Code of Virginia may perform the following duties under supervision of a pharmacist:</p> <ol style="list-style-type: none"> 1. The entry of drug dispensing information and drug history into a data system or other recordkeeping system. 2. The preparation of labels for dispensing the cannabis product or patient information. 3. The removal of the cannabis product to be dispensed from inventory. 4. The measuring of the cannabis product to be dispensed. 5. The packaging and labeling of the cannabis product to be dispensed and the repackaging thereof; 6. The stocking or loading of devices used in the dispensing process. 7. The selling of the cannabis product to the registered patient, parent, legal guardian or registered agent. 8. The performance of any other task restricted to pharmacy technicians by the board's regulations. 		

P applies to Pharmaceutical Processor. D applies to Dispensing Facility		Result	Notes
P	A pharmacist with a current, unrestricted license; a registered pharmacy intern who has completed the first professional year of pharmacy school; or a pharmacy technician with a current, unrestricted registration issued by the board may perform duties associated with the cultivation and extraction as authorized by the pharmaceutical processor, and duties associated with the dispensing of the products as authorized by the PIC or as otherwise authorized in law.		
P	A pharmaceutical processor may employ individuals with less than two years of experience to perform cultivation-related duties under the supervision of an individual who has received a degree in a field related to the cultivation of plants or a certification recognized by the board or who has at least two years of experience cultivating plants.		
P	A pharmaceutical processor may employ individuals with less than two years of experience to perform extraction-related duties under the supervision of an individual who has a degree in chemistry or pharmacology or at least two years of experience extracting chemicals from plants.		
P	At no time shall the dispensing area of a pharmaceutical processor operate or be accessed without a pharmacist on duty. At no time shall the cultivation and production area operate or be accessed without an employee on duty who satisfies the requirements for providing direct supervision for the activities in the respective areas.		
PD	No person shall be employed by or serve as an agent of a pharmaceutical processor or cannabis dispensing facility without being at least 18 years of age.		
	No person who has had a license or registration suspended or revoked or been denied issuance of such license or registration shall serve as an employee or agent of the pharmaceutical processor or cannabis dispensing facility unless such license or registration has been reinstated and is current and unrestricted.		
Employee Training			18 VAC 110-60-180
PD	All employees of a pharmaceutical processor or cannabis dispensing facility shall complete training prior to the employee commencing work at the pharmaceutical processor or cannabis dispensing facility. At a minimum, the training shall be in the following areas:		
	<ol style="list-style-type: none"> 1. The proper use of security measures and controls that have been adopted for the prevention of diversion, theft, or loss of Cannabis, to include the seeds, any parts or extracts of the Cannabis plants and cannabis products. 2. Procedures and instructions for responding to an emergency. 3. Professional conduct, ethics, and state and federal statutes and regulations regarding patient confidentiality. 4. Developments in the field of the medical use of cannabis products. 		
	Prior to regular performance of assigned tasks, the employee shall also receive on-the-job training and other related education, which shall be commensurate with the tasks assigned to the employee.		
	The PIC and the responsible party shall assure the continued competency of all employees, in the respective areas for which they have oversight, through continuing in-service training that is provided at least annually, is designed to supplement initial training, and includes any guidance specified by the board.		

P applies to Pharmaceutical Processor. D applies to Dispensing Facility		Result	Notes
PD	The PIC and the responsible party shall be responsible for maintaining a written record documenting the initial and continuing training of all their respective employees, which shall contain: <ol style="list-style-type: none"> 1. The name of the person receiving the training. 2. The dates of the training. 3. A general description of the topics covered. 4. The name of the person supervising the training. 5. The signatures of the person receiving the training and the PIC or the responsible party. 		
	When a change of pharmaceutical processor or cannabis dispensing facility PIC or responsible party occurs, the new PIC or responsible party shall review the training record and sign it, indicating that the new PIC or responsible party understands its contents.		
	A pharmaceutical processor or cannabis dispensing facility shall maintain the record documenting the employee training and make it available in accordance with regulations.		
Pharmacy Technicians			18 VAC 110-60-190
PD	The ratio of pharmacy technicians to pharmacists on duty in the areas of a pharmaceutical processor or cannabis dispensing facility designated for production or dispensing shall not exceed six pharmacy technicians to one pharmacist.		
	The pharmacist providing direct supervision of pharmacy technicians may be held responsible for the pharmacy technicians' actions. Any violations relating to the dispensing of cannabis products resulting from the actions of a pharmacy technician shall constitute grounds for action against the license of the pharmacist and the registration of the pharmacy technician. As used in this subsection, "direct supervision" means a supervising pharmacist who: Is on duty where the pharmacy technician is performing routine cannabis product production or dispensing functions; and conducts in-process and final checks on the pharmacy technician's performance.		
PD	Pharmacy technicians shall not: <ol style="list-style-type: none"> 1. Counsel a registered patient or the patient's parent, legal guardian, or registered agent regarding cannabis products or other drugs, either before or after cannabis products have been dispensed, or regarding any medical information contained in a patient medication record. 2. Consult with the practitioner who certified the qualifying patient, or the practitioner's agent, regarding a patient or any medical information pertaining to the patient's cannabis product or any other drug the patient may be taking. 3. Interpret the patient's clinical data or provide medical advice. 4. Determine whether a different formulation of cannabidiol products should be substituted for the cannabis product or formulation recommended by the practitioner or requested by the registered patient or parent or legal guardian. 5. Communicate with a practitioner who certified a registered patient, or the practitioner's agent, to obtain a clarification on a qualifying patient's written certification or instructions. 		
	Responsible Party Responsibilities		
P	A person may only serve as the responsible party for one pharmaceutical processor at any one time. The responsible party shall be employed full time in a managerial position at the location of the processor and shall be actively engaged in daily operations of the processor during normal hours of operation.		
	The responsible party shall be aware of and knowledgeable about all policies and procedures pertaining to the operations of the pharmaceutical processor.		
	The responsible party shall ensure compliance with all security measures to protect the Cannabis within the cultivation and production areas from diversion at all times and ensure that cultivation and production is performed in a safe and compliant manner and free of adulteration and misbranding.		

P applies to Pharmaceutical Processor. D applies to Dispensing Facility		Result	Notes
P	The responsible party shall be responsible for ensuring that:		
	<ol style="list-style-type: none"> 1. All employees practicing in the cultivation and production areas are properly trained; 2. All record retention requirements are met 3. All requirements for the physical security of the Cannabis, to include the seeds, any parts or extracts of the Cannabis plants and the cannabis products, within the cultivation and production area are met; and 4. Any other required filings or notifications regarding the cultivation and production areas are made on behalf of the processor as set forth in regulation. 		
P	When the responsible party ceases practice at a pharmaceutical processor or no longer wishes to be designated as the responsible party, he shall immediately return the pharmaceutical processor permit to the board indicating the effective date on which he ceased to be the responsible party.		
P	An application for a permit designating the new responsible party shall be filed with the required fee within 14 days of the original date of resignation or termination of the responsible party on a form provided by the board.		
PIC Responsibilities			18 VAC 110-60-200
PD	The PIC of a pharmaceutical processor shall not serve as PIC of any other facility at any one time. A processor shall employ the PIC at the pharmaceutical processor for at least 35 hours per week, except as otherwise authorized by the board. A person may serve simultaneously as the PIC for no more than two cannabis dispensing facilities located within the same health service area at any one time.		
	The PIC or the pharmacist on duty shall control all aspects of the practice in the dispensing area of the pharmaceutical processor or in a cannabis dispensing facility.		
	The PIC of a pharmaceutical processor or PIC cannabis dispensing facility shall be responsible for ensuring that:		
	<ol style="list-style-type: none"> 1. Pharmacy technicians are registered and properly trained. 2. All record retention requirements pertaining to the dispensing area are met. 3. All requirements for the physical security of the cannabis products are met. 4. The pharmaceutical processor or cannabis dispensing facility has appropriate pharmaceutical reference materials to ensure that cannabis products can be properly dispensed. 		
	<ol style="list-style-type: none"> 5. The following items are conspicuously posted in the pharmaceutical processor or cannabis dispensing facility in a location and in a manner so as to be clearly and readily identifiable to registered patients, parents, legal guardians, or registered agents: <ol style="list-style-type: none"> a. Pharmaceutical processor permit or cannabis dispensing facility permit. b. Licenses for all pharmacists practicing at the pharmaceutical processor or cannabis dispensing facility. c. The price of all cannabis products offered by the pharmaceutical processor or cannabis dispensing facility. 6. Any other required filings or notifications are made on behalf of the dispensing area of the pharmaceutical processor or the dispensing facility as set forth in regulation. 		
	When the PIC ceases practice at a pharmaceutical processor or cannabis dispensing facility or no longer wishes to be designated as PIC, he shall immediately return the permit to the board indicating the effective date on which he ceased to be the PIC.		

P applies to Pharmaceutical Processor. D applies to Dispensing Facility		Result	Notes
PD	An application for a permit designating the new PIC shall be filed with the required fee within 14 days of the original date of resignation or termination of the PIC on a form provided by the board.		
Prescription Monitoring Program			§54.1-2521
PD	Upon dispensing a covered substance, a dispenser of such covered substance shall submit a report to the Prescription monitoring program. The reports required herein shall be made to the Department or its agent within 24 hours or the dispenser's next business day, whichever comes later, and shall be made and transmitted in such manner and format and according to the standards and schedule established in the Department's regulations.		
§54.1-2519: "Covered substance" means all controlled substances included in Schedules II, III, and IV; controlled substances included in Schedule V for which a prescription is required; naloxone; and all drugs of concern that are required to be reported to the Prescription Monitoring Program, pursuant to this chapter. "Covered substance" also includes cannabis products dispensed by a pharmaceutical processor in Virginia.			

Operations			
P applies to Pharmaceutical Processor. D applies Dispensing Facility		Result	Notes
	Processor Permit		§54.1-3442.6
P	A pharmaceutical processor may acquire oil from industrial hemp extract processed in Virginia, and in compliance with state or federal law, from a registered industrial hemp dealer or processor. A pharmaceutical processor may process and formulate such oil extract with cannabis plant extract into an allowable dosage of cannabis oil. Oil from industrial hemp acquired by a pharmaceutical processor is subject to the same third-party testing requirements that may apply to cannabis plant extract. Testing shall be performed by a laboratory located in Virginia and in compliance with state law. The industrial hemp dealer or processor shall provide such third-party testing results to the pharmaceutical processor before oil from industrial hemp may be acquired.		
	Processor Permit		§54.1-3442.7
PD	A pharmaceutical processor or cannabis dispensing facility shall dispense only cannabis products that has been cultivated and produced on the premises of a pharmaceutical processor permitted by the Board or cannabis oil that has been formulated with oil from industrial hemp acquired by a pharmaceutical processor from a registered industrial hemp dealer or processor pursuant to § 54.1-3442.6. A pharmaceutical processor may begin cultivation upon being issued a permit by the Board.		
P	A pharmaceutical processor may begin cultivation upon being issued a permit by the Board.		
	Processor Permit		18 VAC 110-60-130
P	Once the permit is issued, a processor may begin cultivation of Cannabis and the responsible party or a person who is qualified to provide supervision in accordance with 18VAC10-60-170 shall be present during hours of operation to ensure the safety, security and integrity of the Cannabis. Once Cannabis has been placed in the dispensing area of the pharmaceutical processor, a pharmacist shall be present during hours of operation to ensure the safety, security, and integrity of the Cannabis. The responsible party shall ensure security measures are adequate to protect the cannabis in the cultivation and production area from diversion at all times, and the PIC shall have concurrent responsibility for preventing diversion from the dispensing area. If there is a change in the designated opening date, the pharmaceutical processor shall notify the board office, and a pharmacist or the responsible party shall continue to be on site on a daily basis.		
	Notification of Changes		18 VAC 110-60-140
PD	Prior to making any change to the pharmaceutical processor or cannabis dispensing facility name, the pharmaceutical processor or cannabis dispensing facility shall submit an application for such change to the board and pay the fee.		
PD	Any person wishing to engage in the acquisition of an existing pharmaceutical processor or cannabis dispensing facility, change the location of an existing pharmaceutical processor or cannabis dispensing facility, make structural changes to an existing pharmaceutical processor or cannabis dispensing facility, or make changes to a previously approved security system shall submit an application to the board and pay the required fee.		
PD	The proposed location or structural changes shall be inspected by an authorized agent of the board prior to issuance of a permit. Cannabis, oil acquired from industrial hemp extract, or cannabis products shall not be moved to a new location until approval is granted by the inspector or board staff.		

P applies to Pharmaceutical Processor. D applies Dispensing Facility		Result	Notes
Closings, Going Out of Business, Change of Ownership			18 VAC 110-60-150
PD	At least 14 days prior to any change in ownership of an existing pharmaceutical processor or cannabis dispensing facility, the owner shall notify the board of the pending change.		
	Upon any change in ownership of an existing pharmaceutical processor or cannabis dispensing facility, the dispensing records for the two years immediately preceding the date of change of ownership and other required patient information shall be provided to the new owners on the date of change of ownership in substantially the same format as previously used immediately prior to the transfer to provide continuity of services.		
	The previous owner shall be held responsible for assuring the proper and lawful transfer of records on the date of the transfer.		
General Provisions			18 VAC 110-60-210
PD	The PIC, pharmacist, responsible party, or person who is qualified to provide supervision in accordance with 18VAC110-60-170 on duty shall restrict access to the pharmaceutical processor or cannabis dispensing facility to: <ul style="list-style-type: none"> 1. A person whose responsibilities necessitate access to the pharmaceutical processor or cannabis dispensing facility and then for only as long as necessary to perform the person's job duties; or 2. A person who is a registered patient, parent, legal guardian, registered agent, or a companion of the patient in which case such person shall not be permitted behind the service counter or in other areas where Cannabis plants, extracts, or cannabis products are stored. 		
	All pharmacists and pharmacy technicians shall at all times while at the pharmaceutical processor or cannabis dispensing facility have their current license or registration available for inspection by the board or the board's agent.		
	While inside the pharmaceutical processor or cannabis dispensing facility, all employees shall wear name tags or similar forms of identification that clearly identify them, including their position at the pharmaceutical processor or cannabis dispensing facility.		
	A pharmaceutical processor or cannabis dispensing facility shall be open for registered patients, parents, legal guardians, or registered agents to purchase cannabis products for a minimum of 35 hours a week, except as otherwise authorized by the board.		
	A pharmaceutical processor or cannabis dispensing facility that closes the dispensing area during its normal hours of operation shall implement procedures to notify registered patients, parents, legal guardians, and registered agents of when the pharmaceutical processor or cannabis dispensing facility will resume normal hours of operation. Such procedures may include telephone system messages and conspicuously posted signs.		
	If the cultivation, production, or dispensing area of the pharmaceutical processor or if a cannabis dispensing facility is or will be closed during its normal hours of operation for longer than two business days, the pharmaceutical processor or cannabis dispensing facility shall immediately notify the board.		
	A pharmacist shall counsel registered patients, parents, legal guardians, and registered agents, if applicable, regarding the use of cannabis products. Such counseling shall include information related to safe techniques for proper use and storage of cannabis products and for disposal of the products in a manner that renders them nonrecoverable.		
	The pharmaceutical processor or cannabis dispensing facility shall establish, implement, and adhere to a written alcohol-free, drug-free, and smoke-free work place policy that shall be available to the board or the board's agent upon request.		

P applies to Pharmaceutical Processor. D applies Dispensing Facility		Result	Notes
	Advertising		18 VAC 110-60-215
PD	Advertising must accurately and legibly identify the pharmaceutical processor or cannabis dispensing facility responsible for its content and include a statement that cannabis products are for use by registered patients only. Any advertisement for cannabis products that is related to the benefits, safety, or efficacy, including therapeutic or medical claims, shall:		
	1. Be supported by substantial, current clinical evidence or data; and		
	2. Include information on side effects or risks associated with the use of cannabis.		
	Advertising shall not		
	1. Be misleading, deceptive, or false or contain any health-related statement that is untrue in any particular manner or tends to create a misleading impression as to the effects on health of cannabis consumption;		
PD	2. Contain a statement, design, illustration, picture, or representation that <ul style="list-style-type: none"> a. Encourages or represents the recreational use of cannabis; b. Targets or is attractive to persons younger than 18 years of age, including a cartoon character, a mascot, or any other depiction or image that is commonly used to market products to minors; c. Displays the use of cannabis, including the consumption, smoking, or vaping of cannabis; d. Encourages or promotes cannabis for use as an intoxicant; or e. Is obscene or indecent. 		
PD	A pharmaceutical processor or cannabis dispensing facility may list its business in public phone books, business directories, search engines, or other places where it is reasonable for a business to maintain an informational presence of its existence and a description of the nature of the business. A pharmaceutical processor or cannabis dispensing facility shall not engage in the use of pop-up digital advertisements.		
PD	Any website or social media site owned, managed, or operated by a pharmaceutical processor or cannabis dispensing facility shall employ a neutral age-screening mechanism that verifies that the user is at least 18 years of age, including by using an age-gate, age-screen, or age verification mechanism.		
PD	Communication and engagement for educational purposes with registered practitioners, registered patients, parents, legal guardians, registered agents, other health care practitioners, and the general public, including the dissemination of information permitted by 18VAC110-60-215 F and educational materials regarding the use of cannabis products available from the pharmaceutical processor or cannabis dispensing facility, is allowed.		
	No outdoor cannabis product advertising shall be placed within 1,000 feet of (i) a school or daycare; (ii) a public or private playground or similar recreational or child-centered facility; or (iii) a substance use disorder treatment facility.		
	Signs placed on the property of a pharmaceutical processor or cannabis dispensing facility shall not:		
PD	1. Display imagery of cannabis or the use of cannabis or utilize long luminous gas-discharge tubes that contain rarefied neon or other gases; registered agents to find the pharmaceutical processor or cannabis dispensing facility; or		
	2. Draw undue attention to the facility but may be designed to assist registered patients, parents, legal guardians, and		
	3. Be illuminated during non-business hours.		

P applies to Pharmaceutical Processor. D applies Dispensing Facility		Result	Notes
	Prohibitions		18 VAC 110-60-220
P	No pharmaceutical processor shall: <ul style="list-style-type: none"> 1. Cultivate Cannabis plants or produce or dispense cannabis products in any place except the approved facility at the address of record on the application for the pharmaceutical processor permit. 2. Sell, deliver, transport, or distribute Cannabis, including cannabis products, to any other facility except for the wholesale distribution between pharmaceutical processors and to a cannabis dispensing facility pursuant to 18VAC110-60-251. 3. Produce or manufacture cannabis products for use outside of Virginia. 4. Provide cannabis products samples. 		
PD	Except for certain employee access to secured areas designated for cultivation and production and authorized by the responsible party pursuant to § 54.1-3442.6 of the Code of Virginia, no pharmaceutical processor or cannabis dispensing facility shall be open or in operation, and no person shall be in the dispensing area of a pharmaceutical processor or in a cannabis dispensing facility, unless a pharmacist is on the premises and directly supervising the activity within the dispensing area of the pharmaceutical processor or a cannabis dispensing facility. At all other times, the dispensing area of the pharmaceutical processor or the cannabis dispensing facility shall be closed and properly secured.		
PD	No pharmaceutical processor or cannabis dispensing facility shall sell anything other than cannabis products except for devices for administration of dispensed products or hemp based CBD products that meet the applicable standards set forth in state and federal law and that meet testing requirements of 18VAC110-60-280 D 2 and 3.		
	No cannabis products shall be consumed on the premises of a pharmaceutical processor or cannabis dispensing facility, except for emergency administration to a registered patient. Such administration shall be recorded and a file maintained for a period of two years.		
	No person except a pharmaceutical processor or cannabis dispensing facility employee or a registered patient, parent, legal guardian, registered agent or a companion of a patient shall be allowed on the premises of a processor or facility with the following exceptions: laboratory staff may enter a processor for the sole purpose of identifying and collecting Cannabis or cannabis products samples for purposes of conducting laboratory tests; the board or the board's authorized representative may waive the prohibition upon prior written request.		
Notwithstanding the requirements of subsection F of this section, an agent of the board or local law enforcement or other federal, state, or local government officials may enter any area of a pharmaceutical processor or cannabis dispensing facility if necessary to perform their governmental duties.			

P applies to Pharmaceutical Processor. D applies Dispensing Facility		Result	Notes
PD	All persons who have been authorized in writing to enter the facility by the board or the board's authorized representative shall obtain a visitor identification badge from a pharmaceutical processor or cannabis dispensing facility employee prior to entering the processor or facility.		
PD	1. An employee shall escort and monitor an authorized visitor at all times the visitor is in the pharmaceutical processor or cannabis dispensing facility.		
	2. A visitor shall visibly display the visitor identification badge at all times the visitor is in the pharmaceutical processor or cannabis dispensing facility and shall return the visitor identification badge to an employee upon exiting the processor or facility.		
	3. All visitors shall log in and out. The pharmaceutical processor or cannabis dispensing facility shall maintain the visitor log that shall include the date, time, and purpose of the visit and that shall be available to the board.		
	4. If an emergency requires the presence of a visitor and makes it impractical for the pharmaceutical processor or cannabis dispensing facility to obtain a waiver from the board, the processor or cannabis dispensing facility shall provide written notice to the board as soon as practicable after the onset of the emergency. Such notice shall include the name and company affiliation of the visitor, the purpose of the visit, and the date and time of the visit. A pharmaceutical processor or cannabis dispensing facility shall monitor the visitor and maintain a log of such visit as required by this subsection.		
PD	No cannabis products shall be sold, dispensed, or distributed via a delivery service or any other manner outside of a pharmaceutical processor or cannabis dispensing facility, except that a registered parent, legal guardian, or registered agent or an agent of the processor or cannabis dispensing facility may deliver cannabis products to the registered patient or in accordance with 18VAC110-60-310 A.		
Inventory Requirements			18 VAC 110-60-230
PD	Each pharmaceutical processor or cannabis dispensing facility prior to commencing business shall:		
	1. Conduct an initial comprehensive inventory of all Cannabis plants, including the seeds, parts of plants, extracts, and cannabis products, at the facility. The responsible party shall ensure all required inventories are performed in the cultivation and production areas, and the PIC shall ensure all required inventories are performed in the dispensing area. The inventories shall include, at a minimum, the date of the inventory, a summary of the inventory findings, and the name, signature, and title of the pharmacist or pharmacy technician, responsible party, or person authorized by the responsible party who provides supervision of cultivation or production-related activities who conducted the inventory. If a facility commences business with no Cannabis or cannabis products on hand, the pharmacist or responsible party shall record this fact as the initial inventory		
	2. Establish ongoing inventory controls and procedures for the conduct of inventory reviews and comprehensive inventories of all Cannabis plants, including the seeds, parts of plants, extracts, and cannabis products, that shall enable the facility to detect any diversion, theft, or loss in a timely manner.		
P	Upon commencing business, each pharmaceutical processor shall conduct a weekly inventory of all Cannabis plants, including the seeds, parts of plants, and cannabis products in stock, that shall include, at a minimum, the date of the inventory, a summary of the inventory findings, and the name, signature, and title of the pharmacist, pharmacy technician, responsible party, or person authorized by the responsible party who provides supervision of cultivation or production-related activities who conducted the inventory.		

P applies to Pharmaceutical Processor. D applies Dispensing Facility		Result	Notes
D	Upon commencing business, each cannabis dispensing facility shall maintain a perpetual inventory of all cannabis products received and dispensed that accurately indicates the physical count of each cannabis product on hand at the time of performing the inventory. The perpetual inventory shall include a reconciliation of each cannabis product at least monthly with a written explanation for any difference between the physical count and the theoretical count.		
PD	The record of all cannabis products sold, dispensed, or otherwise disposed of shall show the date of sale or disposition; the name of the pharmaceutical processor or cannabis dispensing facility; the name and address of the registered patient, parent, legal guardian, or registered agent to whom the cannabis product was sold; the kind and quantity of cannabis product sold or disposed of; and the method of disposal.		
	A complete and accurate record of all Cannabis plants, including the seeds, parts of plants, and cannabis products on hand shall be prepared annually on the anniversary of the initial inventory or such other date that the PIC or responsible party may choose, so long as it is not more than one year following the prior year's inventory.		
	All inventories, procedures, and other documents required by this section shall be maintained on the premises and made available to the board or its agent.		
	Inventory records shall be maintained for three years from the date the inventory was taken.		
	Whenever any sample or record is removed by a person authorized to enforce state or federal law for the purpose of investigation or as evidence, such person shall tender a receipt in lieu thereof and the receipt shall be kept for a period of at least three years.		
Security Requirements			18 VAC 110-60-240
P	A pharmaceutical processor shall initially cultivate only the number of Cannabis plants necessary to produce cannabis products for the number of patients anticipated within the first nine months of operation. Thereafter, the processor shall not maintain cannabis product in excess of the quantity required for normal efficient operation.		
D	At no time shall a cannabis dispensing facility maintain cannabis products in excess of the quantity required for normal, efficient operation.		
PD	Items a pharmaceutical processor shall properly secure include Cannabis plants, seeds, parts of plants, extracts and cannabis products. A cannabis dispensing facility shall properly secure cannabis products. To secure these items a pharmaceutical processor and a cannabis dispensing facility shall:		
	1. Maintain all Cannabis plants, seeds, parts of plants, extracts, and cannabis products in a secure area or location accessible only by the minimum number of authorized employees essential for efficient operation.		
	2. Store all cut parts of Cannabis plants, extracts, or cannabis products in an approved safe or approved vault within the pharmaceutical processor or cannabis dispensing facility and not sell cannabis oil products when the pharmaceutical processor or cannabis dispensing facility is closed.		
	3. Keep all approved safes, approved vaults, or any other approved equipment or areas used for the production, cultivation, harvesting, processing, manufacturing, or storage of cannabis products securely locked or protected from entry, except for the actual time required to remove or replace the Cannabis, seeds, parts of plants, extracts, or cannabis products;		
	4. Keep all locks and security equipment in good working order.		
	5. Restrict access to keys or codes to all safes, approved vaults, or other approved equipment or areas in the dispensing area to pharmacists practicing at the pharmaceutical processor or cannabis dispensing facility.		

P applies to Pharmaceutical Processor. D applies Dispensing Facility		Result	Notes
P	6. Restrict access to keys or codes to all safes, approved vaults, or other approved equipment or areas in the cultivation and production areas to the responsible party and to those authorized by the responsible party who shall be the pharmacists practicing in the processor or persons supervising cultivation-related or production-related activities at the processor; and		
PD	7. Not allow keys to be left in the locks or accessible to persons not authorized by the PIC or responsible party.		
PD	Employees, other than a pharmacist or person supervising cultivation-related or production-related activities at the processor, but so designated by the PIC or responsible party, may have the ability to unlock a secured area to gain entrance to perform required job duties, but only during hours of operation of the processor or dispensing facility. At no time shall these employees have access to the security system.		
PD	The pharmaceutical processor or cannabis dispensing facility shall have an adequate security system to prevent and detect diversion, theft, or loss of Cannabis seeds, plants, extracts, or cannabis products. A device for the detection of breaking and a back-up alarm system with an ability to remain operational during a power outage shall be installed in each pharmaceutical processor or cannabis dispensing facility. The installation and the device shall be based on accepted alarm industry standards and subject to the following conditions:		
	1. The device shall be a sound, microwave, photoelectric, ultrasonic, or any other generally accepted and suitable device.		
	2. The device shall be monitored in accordance with accepted industry standards, maintained in operating order, have an auxiliary source of power, and be capable of sending an alarm signal to the monitoring entity when breached if the communication line is not operational.		
	3. The device shall fully protect the entire processor or facility and shall be capable of detecting breaking by any means when activated;		
	4. The device shall include a duress alarm, a panic alarm, and automatic voice dialer.		
	5. Access to the alarm system for the dispensing area of the processor or cannabis dispensing facility shall be restricted to the pharmacists working at the pharmaceutical processor or cannabis dispensing facility, and the system shall be activated whenever the processor or facility is closed for business. Access to the alarm system in areas of a pharmaceutical processor that designated for cultivation and production shall be restricted to the responsible party and to those authorized by the responsible party who shall be the pharmacists practicing at the pharmaceutical processor or person supervising cultivation-related or production-related activities at the processor.		
PD	A pharmaceutical processor or cannabis dispensing facility shall keep the outside perimeter of the premises well-lit.		
PD	A processor or facility shall have video cameras in all areas that may contain Cannabis plants, seeds, parts of plants, extracts, or cannabis products and at all points of entry and exit, which shall be appropriate for the normal lighting conditions of the area under surveillance. Products		
	1. The processor or facility shall direct cameras at all approved safes, approved vaults, dispensing areas, or cannabis product sales areas, and any other area where Cannabis plants, seeds, extracts, or cannabis products are being produced, harvested, manufactured, stored, or handled. At entry and exit points, the processor or facility shall angle cameras so as to allow for the capture of clear and certain identification of any person entering or exiting the facility.		

P applies to Pharmaceutical Processor. D applies Dispensing Facility		Result	Notes
PD	2. The video system shall have:		
	<p>a. A failure notification system that provides an audible, text, or visual notification of any failure in the surveillance system. The failure notification system shall provide an alert to the processor or facility within five minutes of the failure, either by telephone, email, or text message.</p> <p>b. The ability to immediately produce a clear color still photo that is a minimum of 9600 dpi from any camera image (live or recorded).</p> <p>c. A date and time stamp embedded on all recordings. The date and time shall be synchronized and set correctly and shall not significantly obscure the picture.</p> <p>d. The ability to remain operational during a power outage.</p>		
PD	3. All video recordings shall allow for the exporting of still images in an industry standard image format. Exported video shall have the ability to be archived in a proprietary format that ensures authentication of the video and guarantees that no alteration of the recorded image has taken place. Exported video shall also have the ability to be saved in an industry standard file format that can be played on a standard computer operating system. A pharmaceutical processor or cannabis dispensing facility shall erase all recordings prior to disposal or sale of the facility; and		
PD	4. The processor or facility shall make 24-hour recordings from all video cameras available for immediate viewing by the board or the board's agent upon request and shall retain the recordings for at least 30 days. If a processor or facility is aware of a pending criminal, civil, or administrative investigation or legal proceeding for which a recording may contain relevant information, the processor or facility shall retain an unaltered copy of the recording until the investigation or proceeding is closed or the entity conducting the investigation or proceeding notifies the pharmaceutical processor or cannabis dispensing facility PIC that it is not necessary to retain the recording.		
	The processor or facility shall maintain all security system equipment and recordings in a secure location so as to prevent theft, loss, destruction, or alterations. All security equipment shall be maintained in good working order and shall be tested at least every six months.		
	A pharmaceutical processor or cannabis dispensing facility shall limit access to surveillance areas to persons who are essential to surveillance operations, law-enforcement agencies, security system service employees, the board or the board's agent, and others when approved by the board. A processor or facility shall make available a current list of authorized employees and security system service employees who have access to the surveillance room to the processor or facility. The pharmaceutical processor or cannabis dispensing facility shall keep all onsite surveillance rooms locked and shall not use such rooms for any other function.		

P applies to Pharmaceutical Processor. D applies Dispensing Facility		Result	Notes																		
	Storage & Handling		18 VAC 110-60-250																		
PD	A pharmaceutical processor or cannabis dispensing facility shall:																				
	1. Have storage areas that provide adequate lighting, ventilation, sanitation, temperature, and humidity as defined in 18VAC110-60-10 and space, equipment, and security conditions for the cultivation of Cannabis and the production and dispensing of cannabis products.																				
	<table border="1"> <thead> <tr> <th>Room or Phase</th> <th>Temperature</th> <th>Humidity</th> </tr> </thead> <tbody> <tr> <td>Mother room</td> <td>65 - 85° F</td> <td>50% - 75%</td> </tr> <tr> <td>Nursery phase</td> <td>65 - 85° F</td> <td>50% - 75%</td> </tr> <tr> <td>Vegetation phase</td> <td>65 - 85° F</td> <td>50% - 75%</td> </tr> <tr> <td>Flower/harvest phase</td> <td>65 - 85° F</td> <td>40% - 75%</td> </tr> <tr> <td>Drying/extraction rooms</td> <td>< 75° F</td> <td>40% - 75%</td> </tr> </tbody> </table>	Room or Phase	Temperature	Humidity	Mother room	65 - 85° F	50% - 75%	Nursery phase	65 - 85° F	50% - 75%	Vegetation phase	65 - 85° F	50% - 75%	Flower/harvest phase	65 - 85° F	40% - 75%	Drying/extraction rooms	< 75° F	40% - 75%		
	Room or Phase	Temperature	Humidity																		
	Mother room	65 - 85° F	50% - 75%																		
	Nursery phase	65 - 85° F	50% - 75%																		
Vegetation phase	65 - 85° F	50% - 75%																			
Flower/harvest phase	65 - 85° F	40% - 75%																			
Drying/extraction rooms	< 75° F	40% - 75%																			
2. Separate for storage in a quarantined area Cannabis plants, seeds, parts of plants, extracts, including cannabis products, that is outdated, damaged, deteriorated, misbranded, or adulterated, or whose containers or packaging have been opened or breached, until such Cannabis plants, seeds, parts of plants, extracts, or cannabis products are destroyed.																					
3. Be maintained in a clean, sanitary, and orderly condition.																					
4. Be free from infestation by insects, rodents, birds, or vermin of any kind.																					
P	A pharmaceutical processor shall compartmentalize all areas in the facility based on function and shall restrict access between compartments.																				
	The pharmaceutical processor shall:																				
	1. Store all Cannabis, including seeds, parts of plants, extracts, and cannabis products, in the process of production, transfer, or analysis in such a manner as to prevent diversion, theft, or loss.																				
	2. Make Cannabis, including the seeds, parts of plants, extracts, and cannabis products accessible only to the minimum number of specifically authorized employees essential for efficient operation.																				
	3. Return the aforementioned items to their secure location immediately after completion of the production, transfer, or analysis process or at the end of the scheduled business day.																				
If a production process cannot be completed at the end of a working day, the pharmacist, responsible party, or other person authorized by the responsible party to supervise cultivation and production at the processor shall securely lock the processing area or tanks, vessels, bins, or bulk containers containing Cannabis, including the seeds, parts of plants, extracts, and cannabis products, inside an area or building that affords adequate security.																					

P applies to Pharmaceutical Processor. D applies Dispensing Facility		Result	Notes
	Policies & Procedures		18 VAC 110-60-250
P	The processor shall establish, maintain, and comply with written policies and procedures regarding best practices for the secure and proper cultivation of Cannabis and production of cannabis products. These shall include policies and procedures that:		
	<ol style="list-style-type: none"> 1. Restrict movement between compartments. 2. Provide for different colored identification cards for facility employees based on the compartment to which they are assigned at a given time so as to ensure that only employees necessary for a particular function have access to that compartment of the facility. 3. Require pocketless clothing for all employees working in an area containing Cannabis plants, seeds, and extracts, including cannabis oil and cannabis products. 4. Document the chain of custody of all Cannabis plants, parts of plants, seeds, extracts, and cannabis products. 		
D	A cannabis dispensing facility shall establish, maintain, and comply with written policies and procedures regarding best practices for the secure and proper dispensing of cannabis products, including a requirement for pocketless clothing for all facility employees working in an area containing cannabis products.		
PD	The PIC and responsible party of a pharmaceutical processor or the PIC of a cannabis dispensing facility shall establish, maintain, and comply with written policies and procedures for the cultivation, production, security, storage, and inventory of Cannabis, including the seeds, parts of plants, extracts, and the cannabis products, as applicable.		
	Such policies and procedures shall include methods for identifying, recording, and reporting diversion, theft, or loss, and for correcting all errors and inaccuracies in inventories.		
PD	Pharmaceutical processors and cannabis dispensing facilities shall include in their written policies and procedures a process for the following:		
	1. Handling mandatory and voluntary recalls of cannabis products. The process shall be adequate to deal with recalls due to any action initiated at the request of the board and any voluntary action by the pharmaceutical processor or cannabis dispensing facility to (i) remove defective or potentially defective cannabis products from the market or (ii) promote public health and safety by replacing existing cannabis products with improved products or packaging.		
	2. Preparing for, protecting against, and handling any crises that affect the security or operation of any facility in the event of strike, fire, flood, or other natural disaster, or other situations of local, state, or national emergency.		
	3. Ensuring that any outdated, damaged, deteriorated, misbranded, or adulterated Cannabis, including seeds, parts of plants, extracts, and cannabis products, is segregated from all other Cannabis, seeds, parts of plants, extracts, and cannabis products and destroyed. This procedure shall provide for written documentation of the Cannabis, including seeds, parts of plants, extracts, and cannabis products disposition.		
	4. Ensuring the oldest stock of Cannabis, including seeds, parts of plants, extracts, and cannabis products are used first. The procedure may permit deviation from this requirement if such deviation is temporary and appropriate.		

P applies to Pharmaceutical Processor. D applies Dispensing Facility		Result	Notes
Record Keeping Requirements			18 VAC 110-60-260
PD	If a pharmaceutical processor or cannabis dispensing facility uses an electronic system for the storage and retrieval of patient information or other records related to cultivating, producing, and dispensing cannabis products, as applicable, the pharmaceutical processor or cannabis dispensing facility shall use a system that:		
	1. Guarantees the confidentiality of the information contained in the system.		
	2. Is capable of providing safeguards against erasures and unauthorized changes in data after the information has been entered and verified by the pharmacist or responsible party.		
	3. Is capable of being reconstructed in the event of a computer malfunction or accident resulting in the destruction of the data bank.		
PD	All records relating to the inventory, laboratory results, and dispensing shall be maintained for a period of three years and shall be made available to the board upon request.		
Reportable Events & Security			18 VAC 110-60-270
PD	Upon becoming aware of (i) diversion, theft, loss, or discrepancies identified during inventory; (ii) unauthorized destruction of any cannabis products; or (iii) any loss or unauthorized alteration of records related to cannabis products or qualifying patients, a pharmacist, responsible party, pharmaceutical processor or cannabis dispensing facility shall immediately notify appropriate law-enforcement authorities and the board.		
	A pharmacist, responsible party, pharmaceutical processor, or cannabis dispensing facility shall provide the notice required by 18VAC110-60-270 (A) to the board by way of a signed statement that details the circumstances of the event, including an accurate inventory of the quantity and brand names of cannabis product diverted, stolen, lost, destroyed, or damaged and confirmation that the local law-enforcement authorities were notified.		
	A pharmacist, responsible party, pharmaceutical processor, or facility shall make such notice no later than 24 hours after discovery of the event.		
PD	A pharmacist, responsible party, pharmaceutical processor, or cannabis dispensing facility shall notify the board no later than the next business day, followed by written notification no later than 10 business days, of any of the following:		
	<ol style="list-style-type: none"> 1. An alarm activation or other event that requires a response by public safety personnel. 2. A breach of security. 3. The failure of the security alarm system due to a loss of electrical support or mechanical malfunction that is expected to last longer than eight hours. 4. Corrective measures taken, if any. 		
	A pharmacist, responsible party, pharmaceutical processor, or cannabis dispensing facility shall immediately notify the board of an employee convicted of a felony or any offense referenced in § 54.1-3442.6 (J) of the Code of Virginia.		
Devices, Hemp Based CBD Products & Inert Product Samples			18 VAC 110-60-321
PD	A pharmaceutical processor or cannabis dispensing facility may have for sale, on-site, devices intended for the administration of dispensed cannabis products and hemp based CBD products that meet the applicable standards set forth in state and federal law and that meet testing requirements of 18VAC110-60-280 D 2 and D 3..		
	The pharmaceutical processor or cannabis dispensing facility may use and distribute inert product samples that do not contain any active cannabinoids for patient demonstration exclusively at the pharmaceutical processor or cannabis dispensing facility, without the need for a written certification. Such inert product samples may not be sold or further distributed.		

P applies to Pharmaceutical Processor. D applies Dispensing Facility		Result	Notes
	Disposal of Cannabis Products		18 VAC 110-60-330
P	To mitigate the risk of diversion, a pharmaceutical processor shall routinely and promptly dispose of undesired, excess, unauthorized, obsolete, adulterated, misbranded, or deteriorated green waste, extracts, and cannabis products, as applicable. Green waste includes Cannabis plants, seeds and parts of plants. Green waste shall be weighed, ground, and combined with a minimum of 51% non-cannabis waste to render it unrecognizable.		
	The destruction and disposal of green waste, extracts, and cannabis products, as applicable, shall be witnessed by a pharmacist and at least one other employee of the pharmaceutical processor or cannabis dispensing facility, respectively, and shall be conducted under video surveillance.		
	The persons destroying and disposing of the green waste, extracts, or cannabis products shall maintain and make available a separate record of each occurrence of destruction and disposal indicating:		
	<ol style="list-style-type: none"> 1. The date and time of destruction and disposal. 2. The manner of destruction and disposal. 3. The name and quantity of cannabis product and green waste destroyed and disposed of. 4. The signatures of the persons destroying and disposing of the green waste, extracts, or cannabis products. 		
	The record of destruction and disposal shall be maintained at the pharmaceutical processor or cannabis dispensing facility for three years from the date of destruction and disposal.		

Cultivation		
P applies to Pharmaceutical Processor. D applies Dispensing Facility	Result	Notes
Cultivation & Production of Cannabis Products		18 VAC 110-60-280
P	No cannabis products shall have had pesticide chemicals or petroleum-based solvents used during the cultivation, extraction, production, or manufacturing process, except that the board may authorize the use of pesticide chemicals for purposes of addressing an infestation that could result in a catastrophic loss of Cannabis crops.	
	Cultivation methods for Cannabis plants and extraction methods used to produce the cannabis products shall be performed in a manner deemed safe and effective based on current standards or scientific literature.	
	No cannabis products intended to be vaporized or inhaled shall contain vitamin E acetate.	
Any Cannabis plant, seed, parts of plant, extract, or cannabis oil not in compliance with this section shall be deemed adulterated.		
Hemp Extract		18 VAC 110-60-280
P	A pharmaceutical processor may acquire oil from industrial hemp extract for the purpose of formulating such oil extract with cannabis plant extract into allowable dosages of cannabis oil provided:	
	1. The pharmaceutical processor acquires the oil from industrial hemp extract processed in Virginia and in compliance with state or federal law from a registered industrial hemp dealer or processor;	
	2. The oil from industrial hemp acquired by a pharmaceutical processor is subject to the same third-party testing requirements applicable to cannabis plant extract as verified by testing performed by a laboratory located in Virginia and in compliance with state law; and	
	3. The industrial hemp dealer or processor provides such third-party testing results to the pharmaceutical processor before oil from industrial hemp is acquired.	
	A pharmaceutical processor acquiring oil from industrial hemp extract shall ensure receipt of a record of the transaction that shows the date of distribution, the names and addresses of the registered industrial hemp dealer or processor distributing the product and the pharmaceutical processor receiving the product, and the kind and quantity of product being distributed. The record of the transaction shall be maintained by the pharmaceutical processor with its records of receipt. Such records shall be maintained by each pharmaceutical processor for three years.	
A pharmaceutical processor shall maintain policies and procedures for the proper storage and handling of oil from industrial hemp extract, to include a process for executing or responding to mandatory and voluntary recalls in a manner that complies with 18VAC110-60-250.		

P applies to Pharmaceutical Processor. D applies Dispensing Facility		Result	Notes
	Registration of Products		18 VAC 110-60-285
P	A pharmaceutical processor shall assign a brand name to each product of cannabis. The pharmaceutical processor shall register each brand name with the board on a form prescribed by the board prior to any dispensing and shall associate each brand name with a specific laboratory test that includes a terpenes profile and a list of all active ingredients, including:		
	<ol style="list-style-type: none"> 1. Tetrahydrocannabinol (THC). 2. Tetrahydrocannabinol acid (THCA). 3. Cannabidiols (CBD). 4. Cannabidiolic acid (CBDA). For botanical cannabis products, only the total cannabidiol (CBD) and total tetrahydrocannabinol (THC) are required		
	A pharmaceutical processor shall not label two products with the same brand name unless the laboratory test results for each product indicate that they contain the same level of each active ingredient listed in subsection A of this section within a range of 90% to 110%.		

Production		
P applies to Pharmaceutical Processor. D applies Dispensing Facility	Result	Notes
	Production of Cannabis Products	§54.1-3442.7
P	The concentration of delta-9-tetrahydrocannabinol in any cannabis product on site may be up to 10 percent greater than or less than the level of delta-9-tetrahydrocannabinol measured for labeling.	
	A pharmaceutical processor shall :	
	1. Ensure that such concentration in any cannabis product on site is within such range.	
	2. Establish a stability testing schedule of cannabis product.	
	Labeling of Batch of Cannabis Products	18 VAC 110-60-290
P	Cannabis products produced as a batch shall not be adulterated. Cannabis products produced as a batch shall be:	
	1. Processed, packaged, and labeled according to the U.S. Food and Drug Administration's Current Good Manufacturing Practice in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements, 21 CFR Part 111.	
	2. Labeled with:	
	a. The name and address of the pharmaceutical processor.	
	b. The brand name of the cannabis product that was registered with the board pursuant to 18VAC110-20-285.	
	c. A unique serial number that matches the product with the pharmaceutical processor batch and lot number so as to facilitate any warnings or recalls the board or pharmaceutical processor deem appropriate.	
	d. The date of testing and packaging.	
	e. The expiration date which shall be six months or less from the date of packing, unless supported by stability testing.	
	f. The quantity of cannabis products contained in the batch.	
	g. A terpenes profile and a list of all active ingredients, including:	
	i. tetrahydrocannabinol (THC).	
ii. tetrahydrocannabinol acid (THCA).		
iii. cannabidiol (CBD).		
iv. cannabidiolic acid (CBDA).		
For botanical cannabis products, only the total cannabidiol (CBD) and total tetrahydrocannabinol (THC) are required		
h. For cannabis oil products, pass or fail rating based on the laboratory's microbiological, mycotoxins, heavy metals, residual solvents, and pesticide chemical residue analysis, and;		
i. For botanical cannabis products, a pass or fail rating based on the laboratory's microbiological, mycotoxins, heavy metals, pesticide chemical residue analysis, water activity and moisture content, and the potency.		

P applies to Pharmaceutical Processor. D applies Dispensing Facility		Result	Notes
	Laboratory Requirements & Testing		18 VAC 110-60-300
	No pharmaceutical processor shall utilize a laboratory to handle, test, or analyze cannabis products unless such laboratory complies with the requirements of 18VAC110-60-300 - Laboratory requirements		
	After processing and before dispensing the cannabis oil product, a pharmaceutical processor shall make a sample available from each homogenized batch of product for a laboratory to (i) test for microbiological contaminants, mycotoxins, heavy metals, residual solvents, and pesticide chemical residue, and (ii) conduct an active ingredient analysis and terpenes profile. Each laboratory shall determine a valid sample size for testing, which may vary due to sample matrix, analytical method, and laboratory-specific procedures. A minimum sample size of 0.5% of individual units for dispensing or distribution from each homogenized batch of cannabis oil is required to achieve a representative sample for analysis.		
P	A pharmaceutical processor shall make a sample available from each harvest batch of botanical cannabis product to (i) test for microbiological contaminants, mycotoxins, heavy metals, pesticide chemical residue, water activity and moisture content, and (ii) conduct an active ingredient analysis and terpenes profile. In determining the minimum sample size for testing from each batch of botanical cannabis, the certified testing laboratory may determine the minimum sample size. The same must be representative of the entire batch to include selection from various points in the batch lot and be of sufficient sample size to allow for analysis of all required tests.		
	From the time that a batch of cannabis product has been sampled for testing until the laboratory provides the results from its tests and analysis, the pharmaceutical processor shall segregate and withhold from use the entire batch, except the samples that have been removed by the laboratory for testing. During this period of segregation, the pharmaceutical processor shall maintain the batch in a secure, cool, and dry location so as to prevent the batch from becoming contaminated or losing its efficacy.		
PD	Under no circumstances shall a pharmaceutical processor or cannabis dispensing facility sell a cannabis product prior to the time that the laboratory has completed its testing and analysis and provided a certificate of analysis to the pharmaceutical processor or other designated facility employee.		
P	The processor shall require the laboratory to immediately return or properly dispose of any cannabis products and materials upon the completion of any testing, use, or research.		
The items in lines 34 through 46 refer to testing for cannabis oil product 18VAC110-60-300 (G)			
P	If a sample of cannabis oil product does not pass the microbiological, mycotoxin, heavy metal, pesticide chemical residue, or residual solvent test based on the standards set forth in this subsection, the batch may be remediated with further processing. After further processing, the batch shall be retested for microbiological, mycotoxin, heavy metal, pesticide chemical residue, and residual solvent. and an active ingredient analysis and terpenes profile shall be conducted.		
	1. For purposes of the microbiological test, a cannabis oil product sample shall be deemed to have passed if it satisfies the standards set forth in Section 1111 of the United States Pharmacopeia.		

P applies to Pharmaceutical Processor. D applies Dispensing Facility		Result	Notes												
P	2. For purposes of the mycotoxin test, a sample of cannabis oil product shall be deemed to have passed if it meets the following standards:														
	<table border="1"> <thead> <tr> <th>Test Specification</th> <th></th> </tr> </thead> <tbody> <tr> <td>Aflatoxin B1</td> <td><20 ug/kg of Substance</td> </tr> <tr> <td>Aflatoxin B2</td> <td><20 ug/kg of Substance</td> </tr> <tr> <td>Aflatoxin G1</td> <td><20 ug/kg of Substance</td> </tr> <tr> <td>Aflatoxin G2</td> <td><20 ug/kg of Substance</td> </tr> <tr> <td>Ochratoxin A</td> <td><20 ug/kg of Substance</td> </tr> </tbody> </table>	Test Specification		Aflatoxin B1	<20 ug/kg of Substance	Aflatoxin B2	<20 ug/kg of Substance	Aflatoxin G1	<20 ug/kg of Substance	Aflatoxin G2	<20 ug/kg of Substance	Ochratoxin A	<20 ug/kg of Substance		
	Test Specification														
	Aflatoxin B1	<20 ug/kg of Substance													
	Aflatoxin B2	<20 ug/kg of Substance													
	Aflatoxin G1	<20 ug/kg of Substance													
Aflatoxin G2	<20 ug/kg of Substance														
Ochratoxin A	<20 ug/kg of Substance														
P	3. For purposes of the heavy metal test, a sample of cannabis oil product shall be deemed to have passed if it meets the following standards:														
	<table border="1"> <thead> <tr> <th>Metal</th> <th>Limits - parts per million (ppm)</th> </tr> </thead> <tbody> <tr> <td>Arsenic</td> <td><10 ppm</td> </tr> <tr> <td>Cadmium</td> <td><4.1 ppm</td> </tr> <tr> <td>Lead</td> <td><10 ppm</td> </tr> <tr> <td>Mercury</td> <td><2 ppm</td> </tr> </tbody> </table>	Metal	Limits - parts per million (ppm)	Arsenic	<10 ppm	Cadmium	<4.1 ppm	Lead	<10 ppm	Mercury	<2 ppm				
	Metal	Limits - parts per million (ppm)													
	Arsenic	<10 ppm													
Cadmium	<4.1 ppm														
Lead	<10 ppm														
Mercury	<2 ppm														
	For purposes of the pesticide chemical residue test, a sample of cannabis oil product shall be deemed to have passed if it satisfies the most stringent acceptable standard for a pesticide chemical residue in any food item as set forth in Subpart C of the federal Environmental Protection Agency's regulations for Tolerances and Exemptions for Pesticide Chemical Residues in Food, 40 CFR Part 180.														
	For purposes of the active ingredient analysis, a sample of the cannabis oil product shall be tested for: <ul style="list-style-type: none"> a. Tetrahydrocannabinol (THC); b. Tetrahydrocannabinol acid (THC-A); c. Cannabidiols (CBD); and d. Cannabidiolic acid (CBDA). 														
	For the purposes of the residual solvent test, a sample of the cannabis oil product shall be deemed to have passed if it meets the standards and limits recommended by the American Herbal Pharmacopoeia for Cannabis Inflorescence.														
	The items in lines 49 through 59 refer to testing for botanical cannabis product 18VAC110-60-300 (H)														
P	If a sample of botanical cannabis product does not pass the microbiological, mycotoxin, heavy metal, pesticide chemical residue, water activity, or moisture content test based on the standards set forth in this subsection, the batch may be remediated. Once remediated, the batch shall be retested for microbiological, mycotoxin, heavy metal, pesticide chemical residue, water activity, and moisture content, and an active ingredient analysis and terpenes profile shall be conducted. If the botanical cannabis batch fails retesting, it shall be considered usable cannabis and may be processed into cannabis oil, unless the failure is related to pesticide requirements, in which case the batch shall not be considered usable cannabis and shall not be processed into cannabis oil.														
	1. For purposes of the microbiological test, a botanical cannabis product sample shall be deemed to have passed if it satisfies the standards set forth in the most current American Herbal Pharmacopoeia Cannabis Inflorescence Standards of Identity, Analysis, and Quality Control.														

P applies to Pharmaceutical Processor. D applies Dispensing Facility		Result	Notes												
P	2. For purposes of the mycotoxin test, a sample of botanical cannabis product shall be deemed to have passed if it meets the following standards:														
	<table border="1"> <thead> <tr> <th>Test Specification</th> <th></th> </tr> </thead> <tbody> <tr> <td>Aflatoxin B1</td> <td><20 ug/kg of Substance</td> </tr> <tr> <td>Aflatoxin B2</td> <td><20 ug/kg of Substance</td> </tr> <tr> <td>Aflatoxin G1</td> <td><20 ug/kg of Substance</td> </tr> <tr> <td>Aflatoxin G2</td> <td><20 ug/kg of Substance</td> </tr> <tr> <td>Ochratoxin A</td> <td><20 ug/kg of Substance</td> </tr> </tbody> </table>		Test Specification		Aflatoxin B1	<20 ug/kg of Substance	Aflatoxin B2	<20 ug/kg of Substance	Aflatoxin G1	<20 ug/kg of Substance	Aflatoxin G2	<20 ug/kg of Substance	Ochratoxin A	<20 ug/kg of Substance	
	Test Specification														
	Aflatoxin B1	<20 ug/kg of Substance													
	Aflatoxin B2	<20 ug/kg of Substance													
	Aflatoxin G1	<20 ug/kg of Substance													
Aflatoxin G2	<20 ug/kg of Substance														
Ochratoxin A	<20 ug/kg of Substance														
3. For purposes of the heavy metal test, a sample of botanical cannabis product shall be deemed to have passed if it meets the following standards:															
<table border="1"> <thead> <tr> <th>Metal</th> <th>Limits - parts per million (ppm)</th> </tr> </thead> <tbody> <tr> <td>Arsenic</td> <td><10 ppm</td> </tr> <tr> <td>Cadmium</td> <td><4.1 ppm</td> </tr> <tr> <td>Lead</td> <td><10 ppm</td> </tr> <tr> <td>Mercury</td> <td><2 ppm</td> </tr> </tbody> </table>		Metal	Limits - parts per million (ppm)	Arsenic	<10 ppm	Cadmium	<4.1 ppm	Lead	<10 ppm	Mercury	<2 ppm				
Metal	Limits - parts per million (ppm)														
Arsenic	<10 ppm														
Cadmium	<4.1 ppm														
Lead	<10 ppm														
Mercury	<2 ppm														
For purposes of the pesticide chemical residue test, a sample of botanical cannabis product shall be deemed to have passed if it satisfies the most stringent acceptable standard for a pesticide chemical residue in any food item as set forth in Subpart C of the federal Environmental Protection Agency's regulations for Tolerances and Exemptions for Pesticide Chemical Residues in Food, 40 CFR Part 180.															
P	For purposes of the active ingredient analysis, a sample of the botanical cannabis product shall be tested for: a. Tetrahydrocannabinol (THC); c. Cannabidiols (CBD); and														
	For the purposes of water activity and moisture content for botanical cannabis, the product shall be deemed to have passed if the water activity rate does not exceed 0.65Aw and the moisture content does not exceed 15%.														
P	If a sample of cannabis product passes the required tests listed in 18VAC110-60-300 G and H, the entire batch may be utilized by the processor for immediate packaging and labeling for sale. An expiration date shall be assigned to the product that is based upon validated stability testing that addresses product stability when opened and the shelf-life for unopened products, except stability testing shall not be required for cannabis products if the pharmaceutical processor assigns an expiration date of six months or less from the date of packaging.														
	The processor shall require the laboratory to file with the board an electronic copy of each laboratory test result for any batch that does not pass the required tests listed in 18VAC110-60-300 G and H at the same time that it transmits those results to the pharmaceutical processor. In addition, the laboratory shall maintain the laboratory test results and make them available to the board or an agent of the board.														
	Each pharmaceutical processor shall have such laboratory results available upon request to registered patients, parents, legal guardians, or registered agents and registered practitioners who have certified qualifying patients, the board, or an agent of the board.														

Wholesale Distribution			
P applies to Pharmaceutical Processor. D applies Dispensing Facility		Result	Notes
	Wholesale Distribution of Cannabis		18VAC110-60-251
PD	Cannabis oil, cannabis products, botanical cannabis, and usable cannabis from a batch that have passed the tests required in 18VAC110-60-300 G and H and are packaged and labeled for sale with an appropriate expiration date in accordance with 18VAC110-60-300 may be wholesale distributed between pharmaceutical processors and between a pharmaceutical processor and a cannabis dispensing facility		
	Cannabis oil products from a batch that passed the microbiological, mycotoxin, heavy metal, residual solvent, and pesticide chemical residue tests and are packaged and labeled for sale with an appropriate expiration date in accordance with 18VAC110-60-300 may be wholesale distributed between cannabis dispensing facilities		
	A pharmaceutical processor or cannabis dispensing facility wholesale distributing the products shall create a record of the transaction that shows (i) the date of distribution, (ii) the names and addresses of the processor or cannabis dispensing facility distributing the product and the processor or cannabis dispensing facility receiving the product, (iii) the kind and quantity of product being distributed, and (iv) the batch and lot identifying information to include harvest date, testing date, processing or manufacturing date, and expiration date.		
	The record of the transaction shall be maintained by the distributing pharmaceutical processor or cannabis dispensing facility with its records of distribution, and a copy of the record shall be provided to and maintained by the processor or facility receiving the product in its records of receipt		
	Such records shall be maintained by each process or facility for three years in compliance with 18VAC110-60-260.		
	A pharmaceutical processor or cannabis dispensing facility wholesale distributing cannabis products shall provide the receiving processor or cannabis dispensing facility with a copy of the lab results for the distributed product or electronic access to the information that can be shared upon request to registered patients, parents, legal guardians, registered agents, registered practitioners who have certified qualifying patients, or an agent of the board		
	A pharmaceutical processor or cannabis dispensing facility wholesale distributing cannabis products shall store and handle products and maintain policies and procedures, to include a process for executing or responding to mandatory and voluntary recalls, in a manner that complies with 18VAC110-60-250.		
	If a pharmaceutical processor or cannabis dispensing facility wholesale distributing products uses an electronic system for the storage and retrieval of records related to distributing products, the pharmaceutical processor shall use a system that is compliant with 18VAC110-60-260.		

Dispensing			
P applies to Pharmaceutical Processor. D applies Dispensing Facility		Result	Notes
	Dispensing Facility		18VAC110-60-135
PD	Once the facility is in possession of cannabis products, a pharmacist shall be on site at all times during the declared hours of operation.		
	Dispensing of Cannabis Products		§54.1-3442.6
PD	A pharmaceutical processor to whom a permit has been issued by the Board may establish up to five cannabis dispensing facilities for the dispensing of cannabis product that has been cultivated and produced on the premises of a pharmaceutical processor permitted by the Board. Each cannabis dispensing facility shall be located within the same health service area as the pharmaceutical processor.		
	Dispensing of Cannabis Products		§54.1-3442.7
	A pharmaceutical processor or cannabis dispensing facility shall dispense or deliver cannabis products only in person to (i) a patient who is a Virginia resident or temporarily resides in Virginia and has been issued a valid written certification, such patient's registered agent; or (iii) if such patient is a minor or a vulnerable adult as defined in § 18.2-369, such patient's parent or legal guardian who is a Virginia resident or temporarily resides in Virginia.		
	Prior to the initial dispensing of each written certification, the pharmacist or pharmacy technician at the location of the pharmaceutical processor or cannabis dispensing facility shall make and maintain, on site or remotely by electronic means, for two years a paper or electronic copy of the written certification that provides an exact image of the document that is clearly legible; shall view, in person or by audiovisual means, a current photo identification of the patient, registered agent, parent, or legal guardian; and shall verify current board registration of the practitioner and the corresponding patient, registered agent, parent, or legal guardian.		
PD	Prior to any subsequent dispensing of each written certification, the pharmacist, pharmacy technician, or delivery agent shall view the current written certification; a current photo identification of the patient, registered agent, parent, or legal guardian; and the current board registration issued to the patient, registered agent, parent, or legal guardian.		
	No pharmaceutical processor or cannabis dispensing facility shall dispense more than a 90-day supply, as determined by the dispensing pharmacist or certifying practitioner, for any patient during any 90-day period. A pharmaceutical processor or cannabis dispensing facility may dispense less than a 90-day supply of a cannabis product for any patient during any 90-day period; however, a pharmaceutical processor or cannabis dispensing facility may dispense more than one cannabis product to a patient at one time. No more than four ounces of botanical cannabis shall be dispensed for each 30-day period for which botanical cannabis is dispensed.		
	A pharmaceutical processor or cannabis dispensing facility shall dispense only cannabis product that has been cultivated and produced on the premises of a pharmaceutical processor permitted by the Board or cannabis product that has been formulated with oil from industrial hemp acquired by a pharmaceutical processor from a registered industrial hemp dealer or processor pursuant to § 54.1-3442.6.		
PD	The concentration of delta-9-tetrahydrocannabinol in any cannabis products on site may be up to 10 percent greater than or less than the level of delta-9-tetrahydrocannabinol measured for labeling. A pharmaceutical processor and cannabis dispensing facility shall ensure that such concentration in any cannabis product on site is within such range. A pharmaceutical processor producing cannabis products shall establish a stability testing schedule of cannabis products.		

P applies to Pharmaceutical Processor. D applies Dispensing Facility		Result	Notes
	18 VAC 110-60-10: 90-day supply" means the amount of cannabis products reasonably necessary to ensure an uninterrupted availability of supply for a 90-day period for registered patients.		
	General Provisions		18 VAC 110-60-210
PD	Only a pharmacist may dispense cannabis products to registered patients or parents or legal guardians of patients who are minors or incapacitated adults and who are registered with the board, or to a registered agent. A pharmacy technician who meets the requirements of 18VAC110-60-170 C may assist, under the direct supervision of a pharmacist, in the dispensing and selling of cannabis products.		
	Prohibitions		18 VAC 110-60-220
D	No cannabis dispensing facility shall:		
	1. Dispense cannabis products in any place except the approved facility at the address of record on the application for the cannabis dispensing facility permit.		
	2. Sell, deliver, transport, or distribute cannabis products to any other facility, except for wholesale distribution between pharmaceutical processors and to a cannabis dispensing facility pursuant to 18VAC110-60-251.		
	3. Provide cannabis product samples.		
	Dispensing of Cannabis Products		18 VAC 110-60-310
PD	A pharmacist in good faith may dispense cannabis products to any registered patient, parent, or legal guardian as indicated on the written certification or to a registered agent for a specific patient.		
	1. Prior to the initial dispensing of cannabis product pursuant to each written certification, the pharmacist or pharmacy technician at the location of the pharmaceutical processor or cannabis dispensing facility shall view, in person or by audiovisual means, a current photo identification of the patient, parent, legal guardian, or registered agent.		
PD	2. The pharmacist or pharmacy technician shall verify in the Virginia Prescription Monitoring Program of the Department of Health Professions or other program recognized by the board that the registrations are current, the written certification has not expired, and the date and quantity of the last dispensing of cannabis products to the registered patient.		
	3. A pharmacist or pharmacy technician employed by the processor or cannabis dispensing facility shall make a paper or electronic copy of the current written certification that provides an exact image of the document that is clearly legible and shall maintain it on site or by electronic means for two years.		
	4. Prior to any subsequent dispensing, the pharmacist or pharmacy technician shall verify that the written certification on file has not expired. An employee or delivery agency shall view a current photo identification and current registration of the patient, parent, legal guardian, or registered agent and shall maintain record of such viewing in accordance with policies and procedures of the pharmaceutical processor or cannabis dispensing facility.		
PD	A pharmacist may dispense a portion of a registered patient's 90-day supply of cannabis products. The pharmacist may dispense the remaining portion of the 90-day supply of cannabis product at any time except that no registered patient, parent, legal guardian, or registered agent shall receive more than a 90-day supply of cannabis oil for a patient in a 90-day period from any pharmaceutical processor or cannabis dispensing facility. A pharmaceutical processor or cannabis dispensing facility may dispense more than one cannabis product to a patient at one time. However, no more than four ounces of botanical cannabis shall be dispensed for each 30-day period for which botanical cannabis is dispensed. In determining the appropriate amount of cannabis product to be dispensed to a patient, a pharmacist shall consider all cannabis products dispensed and adjust the amount dispensed accordingly.		

P applies to Pharmaceutical Processor. D applies Dispensing Facility		Result	Notes
PD	A dispensing record shall be maintained for three years from the date of dispensing.		
	The cannabis products shall be dispensed in child-resistant packaging, except as provided in 18VAC110-60-210 A. A package shall be deemed child-resistant if it satisfies the standard for "special packaging" as set forth in the Poison Prevention Packaging Act of 1970 Regulations, 16 CFR 1700.1(b)(4).		
	No person except a pharmacist or a pharmacy technician operating under the direct supervision of a pharmacist shall alter, deface, or remove any label so affixed.		
	A pharmacist shall be responsible for verifying the accuracy of the dispensed products in all respects prior to dispensing and shall document that each verification has been performed.		
	A pharmacist shall document a registered patient's self-assessment of the effects of cannabis products in treating the registered patient's diagnosed condition or disease or the symptoms thereof.		
	A pharmaceutical processor or cannabis dispensing facility shall maintain such documentation in writing or electronically for three years from the date of dispensing and such documentation shall be made available in accordance with regulation.		
	A pharmacist shall exercise professional judgment to determine whether to dispense cannabis products to a registered patient, parent, legal guardian, or registered agent if the pharmacist suspects that dispensing cannabis products to the registered patient, parent, legal guardian, or registered agent may have negative health or safety consequences for the registered patient or the public.		
Dispensing of Cannabis Products			54.1-3408.3
PD	"Cannabis oil" means any formulation of processed Cannabis plant extract, which may include industrial hemp extracts, including isolates and distillates, acquired by a pharmaceutical processor pursuant to § 54.1-3442.6, or a dilution of the resin of the Cannabis plant that contains no more than 10 milligrams of delta-9-tetrahydrocannabinol per dose. "Cannabis oil" does not include industrial hemp, as defined in § 3.2-4112, that is grown, dealt, or processed in compliance with state or federal law, unless it has been grown and processed in the Commonwealth by a Registered Industrial Hemp Processor and acquired and formulated by a pharmaceutical processor. "Botanical cannabis" means cannabis that is composed wholly of usable cannabis from the same parts of the same chemovar of cannabis plant. "Cannabis product" means a product that is (i) produced by a pharmaceutical processor, registered with the Board, and compliant with testing requirements and (ii) composed of cannabis oil or botanical cannabis.		
	Cannabis oil - Formulation of processed Cannabis plant extract or a dilution of the resin of the Cannabis plant that contains no more than 10 milligrams of dealt-9 tetrahydrocannabinol per dose:		
Vitamin E Acetate			18VAC110-60-280
PD	No cannabis products intended to be vaporized or inhaled shall contain vitamin E acetate.		
Labeling of Dispensed Cannabis Products			18 VAC 110-60-310
PD	The pharmacist or pharmacy technician under the direct supervision of the pharmacist shall affix a label to the container of cannabis product that contains:		
	1. A serial number assigned to the dispensing of the product.		
	2. The brand name of cannabis product that was registered with the board pursuant to 18VAC110-60-285 and its strength.		
	3. The serial number assigned to the product during production.		
	4. The date of dispensing the cannabis product.		
	5. The quantity of cannabis products dispensed.		
	6. A terpenes profile and a list of all active ingredients, including: <ul style="list-style-type: none"> a. Tetrahydrocannabinol (THC). b. Tetrahydrocannabinol acid (THC-A). c. Cannabidiol (CBD). d. Cannabidiolic acid (CBDA) 		
For botanical cannabis products, only the total cannabidiol (CBD) and total tetrahydrocannabinol (THC) are required			

P applies to Pharmaceutical Processor. D applies Dispensing Facility		Result	Notes
PD	7. A pass rating based on the laboratory's microbiological, mycotoxins, heavy metals, residual solvents, pesticide chemical residue analysis, and for botanical cannabis, the water activity and moisture content analysis.		
	8. The name and registration number of the registered patient.		
	9. The name and registration number of the certifying practitioner.		
	10. Directions for use as may be included in the practitioner's written certification or otherwise provided by the practitioner.		
	11. For botanical cannabis, the amount recommended by the practitioner or dispensing pharmacist		
	12. The name or initials of the dispensing pharmacist.		
	13. Name, address, and telephone number of the pharmaceutical processor or cannabis dispensing facility.		
	14. Any necessary cautionary statement.		
	15. A prominently printed expiration date based on stability testing and the pharmaceutical processor's or cannabis dispensing facility's recommended conditions of use and storage that can be read and understood by the ordinary individual.		
A pharmaceutical processor shall not label cannabis products as "organic" unless the Cannabis plants have been organically grown and the cannabis oil products have been produced, processed, manufactured, and certified to be consistent with organic standards in compliance with 7 CFR Part 205.			
Quality Assurance Program			
Dispensing Error Review, Reporting, Quality Assurance Program			18 VAC 110-60-320
PD	A pharmaceutical processor or cannabis dispensing facility shall implement and comply with a quality assurance program that describes, in writing, policies and procedures to detect, identify, and prevent dispensing errors.		
	A pharmaceutical processor or cannabis dispensing facility shall distribute the written policies and procedures to all pharmaceutical processor or cannabis dispensing facility employees and shall make the written policies and procedures readily available on the premises of the pharmaceutical processor or cannabis dispensing facility.		
PD	The policies and procedures shall include:		
	1. Directions for communicating the details of a dispensing error to the practitioner who certified a qualifying patient and to the qualifying patient, the patient's parent or legal guardian, the patient's registered agent, or appropriate family member if the patient is deceased or is unable to fully comprehend the communication. The communication shall describe methods of correcting the dispensing error or reducing the negative impact of the error on the qualifying patient.		
	2. A process to document and assess dispensing errors to determine the cause of the error and an appropriate response.		
PD	A pharmaceutical processor or cannabis dispensing facility shall use the findings of its quality assurance program to develop systems and workflow processes designed to prevent dispensing errors. A pharmaceutical processor or cannabis dispensing facility PIC shall:		
	1. Inform pharmaceutical processor or cannabis dispensing facility employees of changes to policy, procedure, systems, or processes made as a result of recommendations generated by the quality assurance program.		
	2. Notify all processor or facility employees that the discovery or reporting of a dispensing error shall be relayed immediately to a pharmacist on duty.		
	3. Ensure that a pharmacist performs a quality assurance review for each dispensing error. A pharmacist shall commence such review as soon as is reasonably possible, but no later than two business days from the date the dispensing error is discovered.		

P applies to Pharmaceutical Processor. D applies Dispensing Facility		Result	Notes
PD	4. Create a record of every quality assurance review. This record shall contain at least the following:		
	a. The date of the quality assurance review and the names and titles of the persons performing the review.		
	b. The pertinent data and other information relating to the dispensing error reviewed.		
	c. Documentation of contact with the registered patient, parent, legal guardian, or registered agent where applicable, and the practitioner who certified the patient.		
	d. The findings and determinations generated by the quality assurance review.		
	e. Recommended changes to pharmaceutical processor or cannabis dispensing facility policy, procedure, systems, or processes if any.		
	A pharmaceutical processor or cannabis dispensing facility shall maintain for three years a copy of the pharmaceutical processor's or cannabis dispensing facility's quality assurance program and records of all reported dispensing errors and quality assurance reviews in an orderly manner and filed by date.		

Good Manufacturing Practices			
Title 21: Food & Drugs PART 111—CURRENT GOOD MANUFACTURING PRACTICE IN MANUFACTURING, PACKAGING, LABELING, OR HOLDING OPERATIONS FOR DIETARY SUPPLEMENTS			
		Result	Notes
	Subpart B—Personnel		
111.8	Written Procedures		
	You must establish and follow written procedures for fulfilling the requirements of this subpart.		
111.10	Preventing microbial contamination		
	<p>(a) <i>Preventing microbial contamination.</i> You must take measures to exclude from any operations any person who might be a source of microbial contamination, due to a health condition, where such contamination may occur, of any material, including components, dietary supplements, and contact surfaces used in the manufacture, packaging, labeling, or holding of a dietary supplement. Such measures include the following:</p> <p>(1) Excluding from working in any operations that may result in contamination any person who, by medical examination, the person's acknowledgement, or supervisory observation, is shown to have, or appears to have, an illness, infection, open lesion, or any other abnormal source of microbial contamination, that could result in microbial contamination of components, dietary supplements, or contact surfaces, until the health condition no longer exists; and</p> <p>(2) Instructing your employees to notify their supervisor(s) if they have or if there is a reasonable possibility that they have a health condition described in paragraph (a)(1) of this section that could result in microbial contamination of any components, dietary supplements, or any contact surface.</p> <p>(b) <i>Hygienic practices.</i> If you work in an operation during which adulteration of the component, dietary supplement, or contact surface could occur, you must use hygienic practices to the extent necessary to protect against such contamination of components, dietary supplements, or contact surfaces. These hygienic practices include the following:</p> <p>(1) Wearing outer garments in a manner that protects against the contamination of components, dietary supplements, or any contact surface;</p> <p>(2) Maintaining adequate personal cleanliness;</p> <p>(3) Washing hands thoroughly (and sanitizing if necessary to protect against contamination with microorganisms) in an adequate hand-washing facility:</p> <p>(i) Before starting work; and</p> <p>(ii) At any time when the hands may have become soiled or contaminated;</p> <p>(4) Removing all unsecured jewelry and other objects that might fall into components, dietary supplements, equipment, or packaging, and removing hand jewelry that cannot be adequately sanitized during periods in which components or dietary supplements are manipulated by hand. If hand jewelry cannot be removed, it must be covered by material that is maintained in an intact, clean, and sanitary condition and that effectively protects against contamination of components, dietary supplements, or contact surfaces;</p> <p>(5) Maintaining gloves used in handling components or dietary supplements in an intact, clean, and sanitary condition. The gloves must be of an impermeable material;</p> <p>(6) Wearing, where appropriate, in an effective manner, hair nets, caps, beard covers, or other effective hair restraints;</p> <p>(7) Not storing clothing or other personal belongings in areas where components, dietary supplements, or any contact surfaces are exposed or where contact surfaces are washed;</p>		

	<p>(8) Not eating food, chewing gum, drinking beverages, or using tobacco products in areas where components, dietary supplements, or any contact surfaces are exposed, or where contact surfaces are washed; and</p> <p>(9) Taking any other precautions necessary to protect against the contamination of components, dietary supplements, or contact surfaces with microorganisms, filth, or any other extraneous materials, including perspiration, hair, cosmetics, tobacco, chemicals, and medicines applied to the skin.</p>		
111.12	Personnel qualification requirements		
	<p>(a) You must have qualified employees who manufacture, package, label, or hold dietary supplements.</p> <p>(b) You must identify who is responsible for your quality control operations. Each person who is identified to perform quality control operations must be qualified to do so and have distinct and separate responsibilities related to performing such operations from those responsibilities that the person otherwise has when not performing such operations.</p> <p>(c) Each person engaged in manufacturing, packaging, labeling, or holding, or in performing any quality control operations, must have the education, training, or experience to perform the person's assigned functions.</p>		
111.13	Supervisor Requirements		
	<p>(a) You must assign qualified personnel to supervise the manufacturing, packaging, labeling, or holding of dietary supplements.</p> <p>(b) Each supervisor whom you use must be qualified by education, training, or experience to</p>		
111.14	Records		
	<p>(a) You must make and keep records required under this subpart B in accordance with subpart P of this part.</p> <p>(b) You must make and keep the following records:</p> <ol style="list-style-type: none"> (1) Written procedures for fulfilling the requirements of this subpart B; and (2) Documentation of training, including the date of the training, the type of training, and the person(s) trained. 		
Subpart C—Physical Plant and Grounds			
111.15	Sanitation Requirements - Physical Plant & Grounds		
	<p>(a) <i>Grounds.</i> You must keep the grounds of your physical plant in a condition that protects against the contamination of components, dietary supplements, or contact surfaces. The methods for adequate ground maintenance include:</p> <ol style="list-style-type: none"> (1) Properly storing equipment, removing litter and waste, and cutting weeds or grass within the immediate vicinity of the physical plant so that it does not attract pests, harbor pests, or provide pests a place for breeding; (2) Maintaining roads, yards, and parking lots so that they do not constitute a source of contamination in areas where components, dietary supplements, or contact surfaces are exposed; (3) Adequately draining areas that may contribute to the contamination of components, dietary supplements, or contact surfaces by seepage, filth or any other extraneous materials, or by providing a breeding place for pests; (4) Adequately operating systems for waste treatment and disposal so that they do not constitute a source of contamination in areas where components, dietary supplements, or contact surfaces are exposed; and (5) If your plant grounds are bordered by grounds not under your control, and if those other grounds are not maintained in the manner described in this section, you must exercise care in the plant by inspection, extermination, or other means to exclude pests, dirt, and filth or any other extraneous materials that may be a source of contamination. <p>(b) <i>Physical plant facilities</i></p> <ol style="list-style-type: none"> (1) You must maintain your physical plant in a clean and sanitary condition; and (2) You must maintain your physical plant in repair sufficient to prevent components, dietary supplements, or contact surfaces from becoming contaminated. 		

	<p>(c) <i>Cleaning compounds, sanitizing agents, pesticides, and other toxic materials.</i></p> <p>(1) You must use cleaning compounds and sanitizing agents that are free from microorganisms of public health significance and that are safe and adequate under the conditions of use.</p> <p>(2) You must not use or hold toxic materials in a physical plant in which components, dietary supplements, or contact surfaces are manufactured or exposed, unless those materials are necessary as follows:</p> <ul style="list-style-type: none"> (i) To maintain clean and sanitary conditions; (ii) For use in laboratory testing procedures; (iii) For maintaining or operating the physical plant or equipment; or (iv) For use in the plant's operations. <p>(3) You must identify and hold cleaning compounds, sanitizing agents, pesticides, pesticide chemicals, and other toxic materials in a manner that protects against contamination of components, dietary supplements, or contact surfaces.</p>		
	<p>(d) <i>Pest control</i></p> <p>(1) You must not allow animals or pests in any area of your physical plant. Guard or guide dogs are allowed in some areas of your physical plant if the presence of the dogs will not result in contamination of components, dietary supplements, or contact surfaces;</p> <p>(2) You must take effective measures to exclude pests from the physical plant and to protect against contamination of components, dietary supplements, and contact surfaces on the premises by pests; and</p> <p>(3) You must not use insecticides, fumigants, fungicides, or rodenticides, unless you take precautions to protect against the contamination of components, dietary supplements, or contact surfaces.</p>		
	<p>(e) <i>Water supply</i></p> <p>(1) You must provide water that is safe and sanitary, at suitable temperatures, and under pressure as needed, for all uses where water does not become a component of the dietary supplement.</p> <p>(2) Water that is used in a manner such that the water may become a component of the dietary supplement, e.g., when such water contacts components, dietary supplements, or any contact surface, must, at a minimum, comply with applicable Federal, State, and local requirements and not contaminate the dietary supplement.</p>		
	<p>(f) <i>Plumbing.</i> The plumbing in your physical plant must be of an adequate size and design and be adequately installed and maintained to:</p> <ul style="list-style-type: none"> (1) Carry sufficient amounts of water to required locations throughout the physical plant; (2) Properly convey sewage and liquid disposable waste from your physical plant; (3) Avoid being a source of contamination to components, dietary supplements, water supplies, or any contact surface, or creating an unsanitary condition; (4) Provide adequate floor drainage in all areas where floors are subject to flooding-type cleaning or where normal operations release or discharge water or other liquid waste on the floor; and (5) Not allow backflow from, or cross connection between, piping systems that discharge waste water or sewage and piping systems that carry water used for manufacturing dietary supplements, for cleaning contact surfaces, or for use in bathrooms or hand-washing facilities. 		
	<p>(g) <i>Sewage disposal.</i> You must dispose of sewage into an adequate sewage system or through other adequate means.</p>		
	<p>(h) <i>Bathrooms.</i> You must provide your employees with adequate, readily accessible bathrooms. The bathrooms must be kept clean and must not be a potential source of contamination to components, dietary supplements, or contact surfaces.</p>		
	<p>(i) <i>Hand-washing facilities.</i> You must provide hand-washing facilities that are designed to ensure that an employee's hands are not a source of contamination of components, dietary supplements, or any contact surface, by providing facilities that are adequate, convenient, and furnish running water at a suitable temperature.</p>		

	<p>(j) <i>Trash disposal</i>. You must convey, store, and dispose of trash to:</p> <ul style="list-style-type: none"> (1) Minimize the development of odors; (2) Minimize the potential for the trash to attract, harbor, or become a breeding place for pests; (3) Protect against contamination of components, dietary supplements, any contact surface, water supplies, and grounds surrounding your physical plant; and (4) Control hazardous waste to prevent contamination of components, dietary supplements, and contact surfaces. 		
	<p>(k) <i>Sanitation supervisors</i>. You must assign one or more employees to supervise overall sanitation. Each of these supervisors must be qualified by education, training, or experience to develop and supervise sanitation procedures.</p>		
111.16	Written Procedures		
	You must establish and follow written procedures for cleaning the physical plant and for pest control.		
111.20	Design & Construction Requirements		
	Any physical plant you use in the manufacture, packaging, labeling, or holding of dietary supplements must:		
	(a) Be suitable in size, construction, and design to facilitate maintenance, cleaning, and sanitizing operations;		
	(b) Have adequate space for the orderly placement of equipment and holding of materials as is necessary for maintenance, cleaning, and sanitizing operations and to prevent contamination and mixups of components and dietary supplements during manufacturing, packaging, labeling, or holding;		
	<p>(c) Permit the use of proper precautions to reduce the potential for mixups or contamination of components, dietary supplements, or contact surfaces, with microorganisms, chemicals, filth, or other extraneous material. Your physical plant must have, and you must use, separate or defined areas of adequate size or other control systems, such as computerized inventory controls or automated systems of separation, to prevent contamination and mixups of components and dietary supplements during the following operations:</p> <ul style="list-style-type: none"> (1) Receiving, identifying, holding, and withholding from use, components, dietary supplements, packaging, and labels that will be used in or during the manufacturing, packaging, labeling, or holding of dietary supplements; (2) Separating, as necessary, components, dietary supplements, packaging, and labels that are to be used in manufacturing from components, dietary supplements, packaging, or labels that are awaiting material review and disposition decision, reprocessing, or are awaiting disposal after rejection; (3) Separating the manufacturing, packaging, labeling, and holding of different product types including different types of dietary supplements and other foods, cosmetics, and pharmaceutical products; (4) Performing laboratory analyses and holding laboratory supplies and samples; (5) Cleaning and sanitizing contact surfaces; (6) Packaging and label operations; and (7) Holding components or dietary supplements. 		

	<p>(d) Be designed and constructed in a manner that prevents contamination of components, dietary supplements, or contact surfaces.</p> <p>(1) The design and construction must include:</p> <ul style="list-style-type: none"> (i) Floors, walls, and ceilings that can be adequately cleaned and kept clean and in good repair; (ii) Fixtures, ducts, and pipes that do not contaminate components, dietary supplements, or contact surfaces by dripping or other leakage, or condensate; (iii) Adequate ventilation or environmental control equipment such as airflow systems, including filters, fans, and other air-blowing equipment, that minimize odors and vapors (including steam and noxious fumes) in areas where they may contaminate components, dietary supplements, or contact surfaces; (iv) Equipment that controls temperature and humidity, when such equipment is necessary to ensure the quality of the dietary supplement; and (v) Aisles or working spaces between equipment and walls that are adequately unobstructed and of adequate width to permit all persons to perform their duties and to protect against contamination of components, dietary supplements, or contact surfaces with clothing or personal contact. <p>(2) When fans and other air-blowing equipment are used, such fans and equipment must be located and operated in a manner that minimizes the potential for microorganisms and particulate matter to contaminate components, dietary supplements, or contact surfaces;</p>		
	<p>(e) Provide adequate light in:</p> <ul style="list-style-type: none"> (1) All areas where components or dietary supplements are examined, processed, or held; (2) All areas where contact surfaces are cleaned; and (3) Hand-washing areas, dressing and locker rooms, and bathrooms. 		
	<p>(f) Use safety-type light bulbs, fixtures, skylights, or other glass or glass-like materials when the light bulbs, fixtures, skylights or other glass or glass-like materials are suspended over exposed components or dietary supplements in any step of preparation, unless your physical plant is otherwise constructed in a manner that will protect against contamination of components or dietary supplements in case of breakage of glass or glass-like materials.</p>		
	<p>(g) Provide effective protection against contamination of components and dietary supplements in bulk fermentation vessels, by, for example:</p> <ul style="list-style-type: none"> (1) Use of protective coverings; (2) Placement in areas where you can eliminate harborage for pests over and around the vessels; (3) Placement in areas where you can check regularly for pests, pest infestation, filth or any other extraneous materials; and (4) Use of skimming equipment. <p>(h) Use adequate screening or other protection against pests, where necessary.</p>		
111.23	Records		
	<p>(a) You must make and keep records required under this subpart C in accordance with subpart P of this part.</p> <p>(b) You must make and keep records of the written procedures for cleaning the physical plant and for pest control.</p> <p>(c) You must make and keep records that show that water, when used in a manner such that the water may become a component of the dietary supplement, meets the requirements of §111.15(e)(2).</p>		

Subpart D—Equipment and Utensils			
111.25	Written Procedures		
	You must establish and follow written procedures for fulfilling the requirements of this subpart D, including written procedures for: <ul style="list-style-type: none"> (a) Calibrating instruments and controls that you use in manufacturing or testing a component or dietary supplement; (b) Calibrating, inspecting, and checking automated, mechanical, and electronic equipment; and (c) Maintaining, cleaning, and sanitizing, as necessary, all equipment, utensils, and any other contact surfaces that are used to manufacture, package, label, or hold components or dietary supplements. 		
111.27	Equipment & Utensils		
	(a) You must use equipment and utensils that are of appropriate design, construction, and workmanship to enable them to be suitable for their intended use and to be adequately cleaned and properly maintained. <ul style="list-style-type: none"> (1) Equipment and utensils include the following: <ul style="list-style-type: none"> (i) Equipment used to hold or convey; (ii) Equipment used to measure; (iii) Equipment using compressed air or gas; (iv) Equipment used to carry out processes in closed pipes and vessels; and (v) Equipment used in automated, mechanical, or electronic systems. (2) You must use equipment and utensils of appropriate design and construction so that use will not result in the contamination of components or dietary supplements with: <ul style="list-style-type: none"> (i) Lubricants; (ii) Fuel; (iii) Coolants; (iv) Metal or glass fragments; (v) Filth or any other extraneous material; (vi) Contaminated water; or (vii) Any other contaminants. (3) All equipment and utensils you use must be: <ul style="list-style-type: none"> (i) Installed and maintained to facilitate cleaning the equipment, utensils, and all adjacent spaces; (ii) Corrosion-resistant if the equipment or utensils contact components or dietary supplements; (iii) Made of nontoxic materials; (iv) Designed and constructed to withstand the environment in which they are used, the action of components or dietary supplements, and, if applicable, cleaning compounds and sanitizing agents; and (v) Maintained to protect components and dietary supplements from being contaminated by any source. (4) Equipment and utensils you use must have seams that are smoothly bonded or maintained to minimize accumulation of dirt, filth, organic material, particles of components or dietary supplements, or any other extraneous materials or contaminants. (5) Each freezer, refrigerator, and other cold storage compartment you use to hold components or dietary supplements: <ul style="list-style-type: none"> (i) Must be fitted with an indicating thermometer, temperature-measuring device, or temperature-recording device that indicates and records, or allows for recording by hand, the temperature accurately within the compartment; and (ii) Must have an automated device for regulating temperature or an automated alarm system to indicate a significant temperature change in a manual operation. 		

	(6) Instruments or controls used in the manufacturing, packaging, labeling, or holding of a dietary supplement, and instruments or controls that you use to measure, regulate, or record temperatures, hydrogen-ion concentration (pH), water activity, or other conditions, to control or prevent the growth of microorganisms or other contamination must be: <ul style="list-style-type: none"> (i) Accurate and precise; (ii) Adequately maintained; and (iii) Adequate in number for their designated uses. 		
	(7) Compressed air or other gases you introduce mechanically into or onto a component, dietary supplement, or contact surface or that you use to clean any contact surface must be treated in such a way that the component, dietary supplement, or contact surface is not contaminated.		
	(b) You must calibrate instruments and controls you use in manufacturing or testing a component or dietary supplement. You must calibrate: <ul style="list-style-type: none"> (1) Before first use; and (2) At the frequency specified in writing by the manufacturer of the instrument and control; or (3) At routine intervals or as otherwise necessary to ensure the accuracy and precision of the instrument and control. 		
	(c) You must repair or replace instruments or controls that cannot be adjusted to agree with the reference standard.		
	(d) You must maintain, clean, and sanitize, as necessary, all equipment, utensils, and any other contact surfaces used to manufacture, package, label, or hold components or dietary supplements. <ul style="list-style-type: none"> (1) Equipment and utensils must be taken apart as necessary for thorough maintenance, cleaning, and sanitizing. (2) You must ensure that all contact surfaces, used for manufacturing or holding low-moisture components or dietary supplements, are in a dry and sanitary condition when in use. When the surfaces are wet-cleaned, they must be sanitized, when necessary, and thoroughly dried before subsequent use. (3) If you use wet processing during manufacturing, you must clean and sanitize all contact surfaces, as necessary, to protect against the introduction of microorganisms into components or dietary supplements. When cleaning and sanitizing is necessary, you must clean and sanitize all contact surfaces before use and after any interruption during which the contact surface may have become contaminated. If you use contact surfaces in a continuous production operation or in consecutive operations involving different batches of the same dietary supplement, you must adequately clean and sanitize the contact surfaces, as necessary. (4) You must clean surfaces that do not come into direct contact with components or dietary supplements as frequently as necessary to protect against contaminating components or dietary supplements. (5) Single-service articles (such as utensils intended for one-time use, paper cups, and paper towels) must be: <ul style="list-style-type: none"> (i) Stored in appropriate containers; and (ii) Handled, dispensed, used, and disposed of in a manner that protects against contamination of components, dietary supplements, or any contact surface. (6) Cleaning compounds and sanitizing agents must be adequate for their intended use and safe under their conditions of use; (7) You must store cleaned and sanitized portable equipment and utensils that have contact surfaces in a location and manner that protects them from contamination. 		

111.30	Mechanical & Electronic Equipment		
	<p>For any automated, mechanical, or electronic equipment that you use to manufacture, package, label, or hold a dietary supplement, you must:</p> <ul style="list-style-type: none"> (a) Design or select equipment to ensure that dietary supplement specifications are consistently met; (b) Determine the suitability of the equipment by ensuring that your equipment is capable of operating satisfactorily within the operating limits required by the process; (c) Routinely calibrate, inspect, or check the equipment to ensure proper performance. Your quality control personnel must periodically review these calibrations, inspections, or checks; (d) Establish and use appropriate controls for automated, mechanical, and electronic equipment (including software for a computer controlled process) to ensure that any changes to the manufacturing, packaging, labeling, holding, or other operations are approved by quality control personnel and instituted only by authorized personnel; and (e) Establish and use appropriate controls to ensure that the equipment functions in accordance with its intended use. These controls must be approved by quality control personnel. 		
111.30	Records		
	<ul style="list-style-type: none"> (a) You must make and keep records required under this subpart D in accordance with subpart P of this part. (b) You must make and keep the following records: <ul style="list-style-type: none"> (1) Written procedures for fulfilling the requirements of this subpart, including written procedures for: <ul style="list-style-type: none"> (i) Calibrating instruments and controls that you use in manufacturing or testing a component or dietary supplement; (ii) Calibrating, inspecting, and checking automated, mechanical, and electronic equipment; and (iii) Maintaining, cleaning, and sanitizing, as necessary, all equipment, utensils, and any other contact surfaces that are used to manufacture, package, label, or hold components or dietary supplements; (2) Documentation, in individual equipment logs, of the date of the use, maintenance, cleaning, and sanitizing of equipment, unless such documentation is kept with the batch record; (3) Documentation of any calibration, each time the calibration is performed, for instruments and controls that you use in manufacturing or testing a component or dietary supplement. In your documentation, you must: <ul style="list-style-type: none"> (i) Identify the instrument or control calibrated; (ii) Provide the date of calibration; (iii) Identify the reference standard used including the certification of accuracy of the known reference standard and a history of recertification of accuracy; (iv) Identify the calibration method used, including appropriate limits for accuracy and precision of instruments and controls when calibrating; (v) Provide the calibration reading or readings found; (vi) Identify the recalibration method used, and reading or readings found, if accuracy or precision or both accuracy and precision limits for instruments and controls were not met; and (vii) Include the initials of the person who performed the calibration and any recalibration. (4) Written records of calibrations, inspections, and checks of automated, mechanical, and electronic equipment; 		

	<p>(5) Backup file(s) of current software programs (and of outdated software that is necessary to retrieve records that you are required to keep in accordance with subpart P of this part, when current software is not able to retrieve such records) and of data entered into computer systems that you use to manufacture, package, label, or hold dietary supplements.</p> <p>(i) Your backup file (e.g., a hard copy of data you have entered, diskettes, tapes, microfilm, or compact disks) must be an exact and complete record of the data you entered.</p> <p>(ii) You must keep your backup software programs and data secure from alterations, inadvertent erasures, or loss; and</p> <p>(6) Documentation of the controls that you use to ensure that equipment functions in accordance with its intended use.</p>		
Subpart E—Production and Process Control System			
111.55	Requirements to implement a production and process control system		
	You must implement a system of production and process controls that covers all stages of manufacturing, packaging, labeling, and holding of the dietary supplement to ensure the quality of the dietary supplement and that the dietary supplement is packaged and labeled as specified in the master manufacturing record.		
111.60	Design requirements for the production and process control system		
	<p>(a) Your production and in-process control system must be designed to ensure that the dietary supplement is manufactured, packaged, labeled, and held in a manner that will ensure the quality of the dietary supplement and that the dietary supplement is packaged and labeled as specified in the master manufacturing record; and</p> <p>(b) The production and in-process control system must include all requirements of subparts E through L of this part and must be reviewed and approved by quality control personnel.</p>		
111.65	Requirements for quality control operations		
	You must implement quality control operations in your manufacturing, packaging, labeling, and holding operations for producing the dietary supplement to ensure the quality of the dietary supplement and that the dietary supplement is packaged and labeled as specified in the master manufacturing record.		
111.70	Specifications		
	<p>(a) You must establish a specification for any point, step, or stage in the manufacturing process where control is necessary to ensure the quality of the dietary supplement and that the dietary supplement is packaged and labeled as specified in the master manufacturing record.</p> <p>(b) For each component that you use in the manufacture of a dietary supplement, you must establish component specifications as follows:</p> <p>(1) You must establish an identity specification;</p> <p>(2) You must establish component specifications that are necessary to ensure that specifications for the purity, strength and composition of dietary supplements manufactured using the components are met; and</p> <p>(3) You must establish limits on those types of contamination that may adulterate or may lead to adulteration of the finished batch of the dietary supplement to ensure the quality of the dietary supplement.</p>		

	<p>(c) For the in-process production:</p> <p>(1) You must establish in-process specifications for any point, step, or stage in the master manufacturing record where control is necessary to help ensure that specifications are met for the identity, purity, strength, and composition of the dietary supplements and, as necessary, for limits on those types of contamination that may adulterate or may lead to adulteration of the finished batch of the dietary supplement;</p> <p>(2) You must provide adequate documentation of your basis for why meeting the in-process specifications, in combination with meeting component specifications, will help ensure that the specifications are met for the identity, purity, strength, and composition of the dietary supplements and for limits on those types of contamination that may adulterate or may lead to adulteration of the finished batch of the dietary supplement; and</p> <p>(3) Quality control personnel must review and approve the documentation that you provide under paragraph (c)(2) of this section.</p> <p>(d) You must establish specifications for dietary supplement labels (label specifications) and for packaging that may come in contact with dietary supplements (packaging specifications). Packaging that may come into contact with dietary supplements must be safe and suitable for its intended use and must not be reactive or absorptive or otherwise affect the safety or quality of the dietary supplement.</p> <p>(e) For each dietary supplement that you manufacture you must establish product specifications for the identity, purity, strength, and composition of the finished batch of the dietary supplement, and for limits on those types of contamination that may adulterate, or that may lead to adulteration of, the finished batch of the dietary supplement to ensure the quality of the dietary supplement.</p> <p>(f) If you receive a product from a supplier for packaging or labeling as a dietary supplement (and for distribution rather than for return to the supplier), you must establish specifications to provide sufficient assurance that the product you receive is adequately identified and is consistent with your purchase order.</p> <p>(g) You must establish specifications for the packaging and labeling of the finished packaged and labeled dietary supplements, including specifications that ensure that you used the specified packaging and that you applied the specified label.</p>		
111.73	Responsibility for determining whether established specifications		
	You must determine whether the specifications you establish under §111.70 are met.		
111.75	Responsibility for determining whether established specifications		
	<p>(a) Before you use a component, you must:</p> <p>(1) (i) Conduct at least one appropriate test or examination to verify the identity of any component that is a dietary ingredient, unless you petition the agency under paragraph (a)(1)(ii) of this section and the agency exempts you from such testing;</p> <p>(ii) You may submit a petition, under 21 CFR 10.30, to request an exemption from the testing requirements in paragraph (a)(1)(i) of this section. The petition must set forth the scientific rationale, and must be accompanied by the supporting data and information, for proposed alternative testing that will demonstrate that there is no material diminution of assurance, compared to the assurance provided by 100 percent identity testing, of the identity of the dietary ingredient before use when the dietary ingredient is obtained from one or more suppliers identified in the petition. If FDA grants the petition, you must conduct the tests and examinations for the dietary ingredient, otherwise required under §111.75(a)(1)(i), under the terms specified by FDA when the petition is granted; and</p>		

	<p>(2) Confirm the identity of other components and determine whether other applicable component specifications established in accordance with §111.70(b) are met. To do so, you must either:</p> <ul style="list-style-type: none"> (i) Conduct appropriate tests or examinations; or (ii) Rely on a certificate of analysis from the supplier of the component that you receive, provided that: <ul style="list-style-type: none"> (A) You first qualify the supplier by establishing the reliability of the supplier's certificate of analysis through confirmation of the results of the supplier's tests or examinations; (B) The certificate of analysis includes a description of the test or examination method(s) used, limits of the test or examinations, and actual results of the tests or examinations; (C) You maintain documentation of how you qualified the supplier; (D) You periodically re-confirm the supplier's certificate of analysis; and (E) Your quality control personnel review and approve the documentation setting forth the basis for qualification (and re-qualification) of any supplier. 		
	<p>(b) You must monitor the in-process points, steps, or stages where control is necessary to ensure the quality of the finished batch of dietary supplement to:</p> <ul style="list-style-type: none"> (1) Determine whether the in-process specifications are met; and (2) Detect any deviation or unanticipated occurrence that may result in a failure to meet specifications. 		
	<p>(c) For a subset of finished dietary supplement batches that you identify through a sound statistical sampling plan (or for every finished batch), you must verify that your finished batch of the dietary supplement meets product specifications for identity, purity, strength, composition, and for limits on those types of contamination that may adulterate or that may lead to adulteration of the finished batch of the dietary supplement. To do so:</p> <ul style="list-style-type: none"> (1) You must select one or more established specifications for identity, purity, strength, composition, and the limits on those types of contamination that may adulterate or that may lead to adulteration of the dietary supplement that, if tested or examined on the finished batches of the dietary supplement, would verify that the production and process control system is producing a dietary supplement that meets all product specifications (or only those product specifications not otherwise exempted from this provision by quality control personnel under paragraph (d) of this section); (2) You must conduct appropriate tests or examinations to determine compliance with the specifications selected in paragraph (c)(1) of this section; (3) You must provide adequate documentation of your basis for determining that compliance with the specification(s) selected under paragraph (c)(1) of this section, through the use of appropriate tests or examinations conducted under paragraph (c)(2) of this section, will ensure that your finished batch of the dietary supplement meets all product specifications for identity, purity, strength, and composition, and the limits on those types of contamination that may adulterate, or that may lead to the adulteration of, the dietary supplement; and (4) Your quality control personnel must review and approve the documentation that you provide under paragraph (c)(3) of this section. 		

	<p>(d) (1) You may exempt one or more product specifications from verification requirements in paragraph (c)(1) of this section if you determine and document that the specifications you select under paragraph (c)(1) of this section for determination of compliance with specifications are not able to verify that the production and process control system is producing a dietary supplement that meets the exempted product specification and there is no scientifically valid method for testing or examining such exempted product specification at the finished batch stage. In such a case, you must document why, for example, any component and in-process testing, examination, or monitoring, and any other information, will ensure that such exempted product specification is met without verification through periodic testing of the finished batch; and</p> <p>(2) Your quality control personnel must review and approve the documentation that you provide under paragraph (d)(1) of this section.</p>		
	<p>(e) Before you package or label a product that you receive for packaging or labeling as a dietary supplement (and for distribution rather than for return to the supplier), you must visually examine the product and have documentation to determine whether the specifications that you established under §111.70 (f) are met.</p>		
	<p>(f) (1) Before you use packaging, you must, at a minimum, conduct a visual identification of the containers and closures and review the supplier's invoice, guarantee, or certification to determine whether the packaging specifications are met; and</p> <p>(2) Before you use labels, you must, at a minimum, conduct a visual examination of the label and review the supplier's invoice, guarantee, or certification to determine whether label specifications are met.</p>		
	<p>(g) You must, at a minimum, conduct a visual examination of the packaging and labeling of the finished packaged and labeled dietary supplements to determine whether you used the specified packaging and applied the specified label.</p>		
	<p>(h) (1) You must ensure that the tests and examinations that you use to determine whether the specifications are met are appropriate, scientifically valid methods.</p> <p>(2) The tests and examinations that you use must include at least one of the following:</p> <ul style="list-style-type: none"> (i) Gross organoleptic analysis; (ii) Macroscopic analysis; (iii) Microscopic analysis; (iv) Chemical analysis; or (v) Other scientifically valid methods. <p>(i) You must establish corrective action plans for use when an established specification is not met.</p>		
111.77	What you must do if established specifications are not met		
	<p>(a) For specifications established under §111.70(a), (b)(2), (b)(3), (c), (d), (e), and (g) that you do not meet, quality control personnel, in accordance with the requirements in subpart F of this part, must reject the component, dietary supplement, package or label unless such personnel approve a treatment, an in-process adjustment, or reprocessing that will ensure the quality of the finished dietary supplement and that the dietary supplement is packaged and labeled as specified in the master manufacturing record. No finished batch of dietary supplements may be released for distribution unless it complies with §111.123(b).</p> <p>(b) For specifications established under §111.70(b)(1) that you do not meet, quality control personnel must reject the component and the component must not be used in manufacturing the dietary supplement.</p> <p>(c) For specifications established under §111.70(f) that you do not meet, quality control personnel must reject the product and the product may not be packaged or labeled for distribution as a dietary supplement.</p>		

111.80	Sample Collection		
	<p>The representative samples that you must collect include:</p> <p>(a) Representative samples of each unique lot of components, packaging, and labels that you use to determine whether the components, packaging, and labels meet specifications established in accordance with §111.70(b) and (d), and as applicable, §111.70(a) (and, when you receive components, packaging, or labels from a supplier, representative samples of each unique shipment, and of each unique lot within each unique shipment);</p> <p>(b) Representative samples of in-process materials for each manufactured batch at points, steps, or stages, in the manufacturing process as specified in the master manufacturing record where control is necessary to ensure the identity, purity, strength, and composition of dietary supplements to determine whether the in-process materials meet specifications established in accordance with §111.70(c), and as applicable, §111.70(a);</p> <p>(c) Representative samples of a subset of finished batches of each dietary supplement that you manufacture, which you identify through a sound statistical sampling plan (or otherwise every finished batch), before releasing for distribution to verify that the finished batch of dietary supplement meets product specifications established in accordance with §111.70(e), and as applicable, §111.70(a);</p> <p>(d) Representative samples of each unique shipment, and of each unique lot within each unique shipment, of product that you receive for packaging or labeling as a dietary supplement (and for distribution rather than for return to the supplier) to determine whether the received product meets specifications established in accordance with §111.70(f), and as applicable, §111.70(a); and</p> <p>(e) Representative samples of each lot of packaged and labeled dietary supplements to determine whether the packaging and labeling of the finished packaged and labeled dietary supplements meet specifications established in accordance with §111.70(g), and as applicable, §111.70(a).</p>		
111.83	Reserve Samples		
	<p>(a) You must collect and hold reserve samples of each lot of packaged and labeled dietary supplements that you distribute.</p> <p>(b) The reserve samples must:</p> <ol style="list-style-type: none"> (1) Be held using the same container-closure system in which the packaged and labeled dietary supplement is distributed, or if distributing dietary supplements to be packaged and labeled, using a container-closure system that provides essentially the same characteristics to protect against contamination or deterioration as the one in which it is distributed for packaging and labeling elsewhere; (2) Be identified with the batch, lot, or control number; (3) Be retained for 1 year past the shelf life date (if shelf life dating is used), or for 2 years from the date of distribution of the last batch of dietary supplements associated with the reserve sample, for use in appropriate investigations; and (4) Consist of at least twice the quantity necessary for all tests or examinations to determine whether or not the dietary supplement meets product specifications. 		
111.87	Material Review & Disposition Decision		
	Quality control personnel must conduct all required material reviews and make all required disposition decisions.		

111.90	Requirements that apply to treatments, in-process adjustments, and reprocessing when there is a deviation or unanticipated occurrence or when a specification established in accordance with §111.70 is not met		
	<p>(a) You must not reprocess a rejected dietary supplement or treat or provide an in-process adjustment to a component, packaging, or label to make it suitable for use in the manufacture of a dietary supplement unless:</p> <ol style="list-style-type: none"> (1) Quality control personnel conduct a material review and make a disposition decision to approve the reprocessing, treatment, or in-process adjustment; and (2) The reprocessing, treatment, or in-process adjustment is permitted by §111.77; <p>(b) You must not reprocess any dietary supplement or treat or provide an in-process adjustment to a component to make it suitable for use in the manufacture of a dietary supplement, unless:</p> <ol style="list-style-type: none"> (1) Quality control personnel conduct a material review and make a disposition decision that is based on a scientifically valid reason and approves the reprocessing, treatment, or in-process adjustment; and (2) The reprocessing, treatment or in-process adjustment is permitted by §111.77; <p>(c) Any batch of dietary supplement that is reprocessed, that contains components that you have treated, or to which you have made in-process adjustments to make them suitable for use in the manufacture of the dietary supplement must be approved by quality control personnel and comply with §111.123(b) before releasing for distribution.</p>		
111.95	Records		
	<p>(a) You must make and keep records required under this subpart E in accordance with subpart P of this part.</p> <p>(b) Under this subpart E, you must make and keep the following records:</p> <ol style="list-style-type: none"> (1) The specifications established; (2) Documentation of your qualification of a supplier for the purpose of relying on the supplier's certificate of analysis; (3) Documentation for why meeting in-process specifications, in combination with meeting component specifications, helps ensure that the dietary supplement meets the specifications for identity, purity, strength, and composition; and for limits on those types of contamination that may adulterate or may lead to adulteration of the finished batch of the dietary supplement; and (4) Documentation for why the results of appropriate tests or examinations for the product specifications selected under §111.75(c)(1) ensure that the dietary supplement meets all product specifications; (5) Documentation for why any component and in-process testing, examination, or monitoring, and any other information, will ensure that a product specification that is exempted under §111.75(d) is met without verification through periodic testing of the finished batch, including documentation that the selected specifications tested or examined under §111.75 (c)(1) are not able to verify that the production and process control system is producing a dietary supplement that meets the exempted product specification and there is no scientifically valid method for testing or examining such exempted product specification at the finished batch stage. (6) Documentation of FDA's response to a petition submitted under §111.75(a)(1)(ii) providing for an exemption from the provisions of §111.75(a)(1)(i). 		

Subpart F— Quality Control			
111.103	Written Procedures		
	You must establish and follow written procedures for the responsibilities of the quality control operations, including written procedures for conducting a material review and making a disposition decision, and for approving or rejecting any reprocessing.		
111.105	Quality Control Personnel		
	<p>Quality control personnel must ensure that your manufacturing, packaging, labeling, and holding operations ensure the quality of the dietary supplement and that the dietary supplement is packaged and labeled as specified in the master manufacturing record. To do so, quality control personnel must perform operations that include:</p> <ul style="list-style-type: none"> (a) Approving or rejecting all processes, specifications, written procedures, controls, tests, and examinations, and deviations from or modifications to them, that may affect the identity, purity, strength, or composition of a dietary supplement; (b) Reviewing and approving the documentation setting forth the basis for qualification of any supplier; (c) Reviewing and approving the documentation setting forth the basis for why meeting in-process specifications, in combination with meeting component specifications, will help ensure that the identity, purity, strength, and composition of the dietary supplement are met; (d) Reviewing and approving the documentation setting forth the basis for why the results of appropriate tests or examinations for each product specification selected under §111.75(c)(1) will ensure that the finished batch of the dietary supplement meets product specifications; (e) Reviewing and approving the basis and the documentation for why any product specification is exempted from the verification requirements in §111.75(c)(1), and for why any component and in-process testing, examination, or monitoring, or other methods will ensure that such exempted product specification is met without verification through periodic testing of the finished batch; (f) Ensuring that required representative samples are collected; (g) Ensuring that required reserve samples are collected and held; (h) Determining whether all specifications established under §111.70(a) are met; and (i) Performing other operations required under this subpart. 		
111.110	Quality control operations for laboratory operations		
	<p>Quality control operations for laboratory operations associated with the production and process control system must include:</p> <ul style="list-style-type: none"> (a) Reviewing and approving all laboratory control processes associated with the production and process control system; (b) Ensuring that all tests and examinations required under §111.75 are conducted; and (c) Reviewing and approving the results of all tests and examinations required under §111.75. 		
111.113	Quality control operations for a material review and disposition decision		
	<p>(a) Quality control personnel must conduct a material review and make a disposition decision if:</p> <ul style="list-style-type: none"> (1) A specification established in accordance with §111.70 is not met; (2) A batch deviates from the master manufacturing record, including when any step established in the master manufacturing record is not completed and including any deviation from specifications; (3) There is any unanticipated occurrence during the manufacturing operations that adulterates or may lead to adulteration of the component, dietary supplement, or packaging, or could lead to the use of a label not specified in the master manufacturing record; 		

	<p>(4) Calibration of an instrument or control suggests a problem that may have resulted in a failure to ensure the quality of a batch or batches of a dietary supplement; or</p> <p>(5) A dietary supplement is returned.</p> <p>(b) (1) When there is a deviation or unanticipated occurrence during the production and in-process control system that results in or could lead to adulteration of a component, dietary supplement, or packaging, or could lead to the use of a label not specified in the master manufacturing record, quality control personnel must reject the component, dietary supplement, packaging, or label unless it approves a treatment, an in-process adjustment, or reprocessing to correct the applicable deviation or occurrence.</p> <p>(2) When a specification established in accordance with §111.70 is not met, quality control personnel must reject the component, dietary supplement, package or label, unless quality control personnel approve a treatment, an in-process adjustment, or reprocessing, as permitted in §111.77.</p> <p>(c) The person who conducts a material review and makes the disposition decision must, at the time of performance, document that material review and disposition decision.</p>		
111.117	Quality control operations for equipment, instruments, and controls		
	<p>Quality control operations for equipment, instruments, and controls must include:</p> <p>(a) Reviewing and approving all processes for calibrating instruments and controls;</p> <p>(b) Periodically reviewing all records for calibration of instruments and controls;</p> <p>(c) Periodically reviewing all records for calibrations, inspections, and checks of automated, mechanical, or electronic equipment; and</p> <p>(d) Reviewing and approving controls to ensure that automated, mechanical, or electronic equipment functions in accordance with its intended use.</p>		
111.120	Quality control operations for components, packaging, and labels before use in the manufacture of a dietary supplement		
	<p>Quality control operations for components, packaging, and labels before use in the manufacture of a dietary supplement must include:</p> <p>(a) Reviewing all receiving records for components, packaging, and labels;</p> <p>(b) Determining whether all components, packaging, and labels conform to specifications established under §111.70 (b) and (d);</p> <p>(c) Conducting any required material review and making any required disposition decision;</p> <p>(d) Approving or rejecting any treatment and in-process adjustments of components, packaging, or labels to make them suitable for use in the manufacture of a dietary supplement; and</p> <p>(e) Approving, and releasing from quarantine, all components, packaging, and labels before they are used.</p>		
111.123	Quality control operations for the master manufacturing record, the batch production record, and manufacturing operations		
	<p>(a) Quality control operations for the master manufacturing record, the batch production record, and manufacturing operations must include:</p> <p>(1) Reviewing and approving all master manufacturing records and all modifications to the master manufacturing records;</p> <p>(2) Reviewing and approving all batch production-related records;</p> <p>(3) Reviewing all monitoring required under subpart E;</p> <p>(4) Conducting any required material review and making any required disposition decision;</p> <p>(5) Approving or rejecting any reprocessing;</p> <p>(6) Determining whether all in-process specifications established in accordance with §111.70(c) are met;</p> <p>(7) Determining whether each finished batch conforms to product specifications established in accordance with §111.70(e); and</p> <p>(8) Approving and releasing, or rejecting, each finished batch for distribution, including any reprocessed finished batch.</p>		

	<p>(b) Quality control personnel must not approve and release for distribution:</p> <p>(1) Any batch of dietary supplement for which any component in the batch does not meet its identity specification;</p> <p>(2) Any batch of dietary supplement, including any reprocessed batch, that does not meet all product specifications established in accordance with §111.70(e);</p> <p>(3) Any batch of dietary supplement, including any reprocessed batch, that has not been manufactured, packaged, labeled, and held under conditions to prevent adulteration under section 402(a)(1), (a)(2), (a)(3), and (a)(4) of the act; and</p> <p>(4) Any product received from a supplier for packaging or labeling as a dietary supplement (and for distribution rather than for return to the supplier) for which sufficient assurance is not provided to adequately identify the product and to determine that the product is consistent with your purchase order.</p>		
111.127	Quality control operations for packaging and labeling operations		
	<p>Quality control operations for packaging and labeling operations must include:</p> <p>(a) Reviewing the results of any visual examination and documentation to ensure that specifications established under §111.70(f) are met for all products that you receive for packaging and labeling as a dietary supplement (and for distribution rather than for return to the supplier);</p> <p>(b) Approving, and releasing from quarantine, all products that you receive for packaging or labeling as a dietary supplement (and for distribution rather than for return to the supplier) before they are used for packaging or labeling;</p> <p>(c) Reviewing and approving all records for packaging and label operations;</p> <p>(d) Determining whether the finished packaged and labeled dietary supplement conforms to specifications established in accordance with §111.70(g);</p> <p>(e) Conducting any required material review and making any required disposition decision;</p> <p>(f) Approving or rejecting any repackaging of a packaged dietary supplement;</p> <p>(g) Approving or rejecting any relabeling of a packaged and labeled dietary supplement; and</p> <p>(h) Approving for release, or rejecting, any packaged and labeled dietary supplement (including a repackaged or relabeled dietary supplement) for distribution.</p>		
111.130	Quality control operations for returned dietary supplements		
	<p>Quality control operations for returned dietary supplements must include:</p> <p>(a) Conducting any required material review and making any required disposition decision; including:</p> <p>(1) Determining whether tests or examination are necessary to determine compliance with product specifications established in accordance with §111.70(e); and</p> <p>(2) Reviewing the results of any tests or examinations that are conducted to determine compliance with product specifications established in accordance with §111.70(e);</p> <p>(b) Approving or rejecting any salvage and redistribution of any returned dietary supplement;</p> <p>(c) Approving or rejecting any reprocessing of any returned dietary supplement; and</p> <p>(d) Determining whether the reprocessed dietary supplement meets product specifications and either approving for release, or rejecting, any returned dietary supplement that is reprocessed.</p>		
111.135	Quality control operations for product complaints		
	<p>Quality control operations for product complaints must include reviewing and approving decisions about whether to investigate a product complaint and reviewing and approving the findings and follow-up action of any investigation performed.</p>		

111.140	Records		
	<p>(a) You must make and keep the records required under this subpart F in accordance with subpart P of this part.</p> <p>(b) You must make and keep the following records:</p> <p>(1) Written procedures for the responsibilities of the quality control operations, including written procedures for conducting a material review and making a disposition decision and written procedures for approving or rejecting any reprocessing;</p> <p>(2) Written documentation, at the time of performance, that quality control personnel performed the review, approval, or rejection requirements by recording the following:</p> <p>(i) Date that the review, approval, or rejection was performed; and</p> <p>(ii) Signature of the person performing the review, approval, or rejection; and</p> <p>(3) Documentation of any material review and disposition decision and follow-up. Such documentation must be included in the appropriate batch production record and must include:</p> <p>(i) Identification of the specific deviation or the unanticipated occurrence;</p> <p>(ii) Description of your investigation into the cause of the deviation from the specification or the unanticipated occurrence;</p> <p>(iii) Evaluation of whether or not the deviation or unanticipated occurrence has resulted in or could lead to a failure to ensure the quality of the dietary supplement or a failure to package and label the dietary supplement as specified in the master manufacturing record;</p> <p>(iv) Identification of the action(s) taken to correct, and prevent a recurrence of, the deviation or the unanticipated occurrence;</p> <p>(v) Explanation of what you did with the component, dietary supplement, packaging, or label;</p> <p>(vi) A scientifically valid reason for any reprocessing of a dietary supplement that is rejected or any treatment or in-process adjustment of a component that is rejected; and</p> <p>(vii) The signature of the individual(s) designated to perform the quality control operation, who conducted the material review and made the disposition decision, and of each qualified individual who provides information relevant to that material review and disposition decision.</p>		
	Subpart G— Requirements for Components, Packaging, and Labels and for Product That You Receive for Packaging or Labeling as a Dietary Supplement		
111.153	Written Procedures		
	You must establish and follow written procedures for fulfilling the requirements of this subpart G.		
111.155	Requirements that apply to components of dietary supplements		
	<p>(a) You must visually examine each immediate container or grouping of immediate containers in a shipment that you receive for appropriate content label, container damage, or broken seals to determine whether the container condition may have resulted in contamination or deterioration of the components;</p> <p>(b) You must visually examine the supplier's invoice, guarantee, or certification in a shipment you receive to ensure the components are consistent with your purchase order;</p> <p>(c) You must quarantine components before you use them in the manufacture of a dietary supplement until:</p> <p>(1) You collect representative samples of each unique lot of components (and, for components that you receive, of each unique shipment, and of each unique lot within each unique shipment);</p> <p>(2) Quality control personnel review and approve the results of any tests or examinations conducted on components; and</p>		

	<p>(3) Quality control personnel approve the components for use in the manufacture of a dietary supplement, including approval of any treatment (including in-process adjustments) of components to make them suitable for use in the manufacture of a dietary supplement, and releases them from quarantine.</p> <p>(d) (1) You must identify each unique lot within each unique shipment of components that you receive and any lot of components that you produce in a manner that allows you to trace the lot to the supplier, the date received, the name of the component, the status of the component (e.g., quarantined, approved, or rejected); and to the dietary supplement that you manufactured and distributed.</p> <p>(2) You must use this unique identifier whenever you record the disposition of each unique lot within each unique shipment of components that you receive and any lot of components that you produce.</p> <p>(e) You must hold components under conditions that will protect against contamination and deterioration, and avoid mix-ups.</p>		
111.160	Requirements that apply to packaging and labels received		
	<p>(a) You must visually examine each immediate container or grouping of immediate containers in a shipment for appropriate content label, container damage, or broken seals to determine whether the container condition may have resulted in contamination or deterioration of the packaging and labels.</p> <p>(b) You must visually examine the supplier's invoice, guarantee, or certification in a shipment to ensure that the packaging or labels are consistent with your purchase order.</p> <p>(c) You must quarantine packaging and labels before you use them in the manufacture of a dietary supplement until:</p> <p>(1) You collect representative samples of each unique shipment, and of each unique lot within each unique shipment, of packaging and labels and, at a minimum, conduct a visual identification of the immediate containers and closures;</p> <p>(2) Quality control personnel review and approve the results of any tests or examinations conducted on the packaging and labels; and</p> <p>(3) Quality control personnel approve the packaging and labels for use in the manufacture of a dietary supplement and release them from quarantine.</p> <p>(d) (1) You must identify each unique lot within each unique shipment of packaging and labels in a manner that allows you to trace the lot to the supplier, the date received, the name of the packaging and label, the status of the packaging and label (e.g., quarantined, approved, or rejected); and to the dietary supplement that you distributed; and</p> <p>(2) You must use this unique identifier whenever you record the disposition of each unique lot within each unique shipment of packaging and labels.</p> <p>(e) You must hold packaging and labels under conditions that will protect against contamination and deterioration, and avoid mix-ups.</p>		
111.165	§111.165 What requirements apply to a product received for packaging or labeling as a dietary supplement (and for distribution rather than for return to the supplier)?		
	<p>(a) You must visually examine each immediate container or grouping of immediate containers in a shipment of product that you receive for packaging or labeling as a dietary supplement (and for distribution rather than for return to the supplier) for appropriate content label, container damage, or broken seals to determine whether the container condition may have resulted in contamination or deterioration of the received product.</p> <p>(b) You must visually examine the supplier's invoice, guarantee, or certification in a shipment of the received product to ensure that the received product is consistent with your purchase order.</p>		

	<p>(c) You must quarantine the received product until:</p> <p>(1) You collect representative samples of each unique shipment, and of each unique lot within each unique shipment, of received product;</p> <p>(2) Quality control personnel review and approve the documentation to determine whether the received product meets the specifications that you established under §111.70(f); and</p> <p>(3) Quality control personnel approve the received product for packaging or labeling as a dietary supplement and release the received product from quarantine.</p> <p>(d) (1) You must identify each unique lot within each unique shipment of received product in a manner that allows you to trace the lot to the supplier, the date received, the name of the received product, the status of the received product (e.g., quarantined, approved, or rejected), and to the product that you packaged or labeled and distributed as a dietary supplement.</p> <p>(2) You must use this unique identifier whenever you record the disposition of each unique lot within each unique shipment of the received product.</p> <p>(e) You must hold the received product under conditions that will protect against contamination and deterioration, and avoid mix-ups.</p>		
111.170	Requirements that apply to rejected components, packaging, and labels, and to rejected products that are received for packaging or labeling as a dietary supplement		
	You must clearly identify, hold, and control under a quarantine system for appropriate disposition any component, packaging, and label, and any product that you receive for packaging or labeling as a dietary supplement (and for distribution rather than for return to the supplier), that is rejected and unsuitable for use in manufacturing, packaging, or labeling operations.		
111.180	Records		
	<p>(a) You must make and keep records required under this subpart G in accordance with subpart P of this part.</p> <p>(b) You must make and keep the following records:</p> <p>(1) Written procedures for fulfilling the requirements of this subpart.</p> <p>(2) Receiving records (including records such as certificates of analysis, suppliers' invoices, and suppliers' guarantees) for components, packaging, and labels and for products that you receive for packaging or labeling as a dietary supplement (and for distribution rather than for return to the supplier); and</p> <p>(3) Documentation that the requirements of this subpart were met.</p> <p>(i) The person who performs the required operation must document, at the time of performance, that the required operation was performed.</p> <p>(ii) The documentation must include:</p> <p>(A) The date that the components, packaging, labels, or products that you receive for packaging or labeling as a dietary supplement were received;</p> <p>(B) The initials of the person performing the required operation;</p> <p>(C) The results of any tests or examinations conducted on components, packaging, or labels, and of any visual examination of product that you receive for packaging or labeling as a dietary supplement; and</p> <p>(D) Any material review and disposition decision conducted on components, packaging, labels, or products that you receive for packaging or labeling as a dietary supplement.</p>		

Subpart H—Requirements for the Master Manufacturing Record			
111.205	Master Manufacturing Record		
	<p>(a) You must prepare and follow a written master manufacturing record for each unique formulation of dietary supplement that you manufacture, and for each batch size, to ensure uniformity in the finished batch from batch to batch.</p> <p>(b) The master manufacturing record must:</p> <ol style="list-style-type: none"> (1) Identify specifications for the points, steps, or stages in the manufacturing process where control is necessary to ensure the quality of the dietary supplement and that the dietary supplement is packaged and labeled as specified in the master manufacturing record; and (2) Establish controls and procedures to ensure that each batch of dietary supplement that you manufacture meets the specifications identified in accordance with paragraph (b)(1) of this section. <p>(c) You must make and keep master manufacturing records in accordance with subpart P of this part.</p>		
111.210	Master Manufacturing Record Content		
	<p>The master manufacturing record must include:</p> <p>(a) The name of the dietary supplement to be manufactured and the strength, concentration, weight, or measure of each dietary ingredient for each batch size;</p> <p>(b) A complete list of components to be used;</p> <p>(c) An accurate statement of the weight or measure of each component to be used;</p> <p>(d) The identity and weight or measure of each dietary ingredient that will be declared on the Supplement Facts label and the identity of each ingredient that will be declared on the ingredients list of the dietary supplement;</p> <p>(e) A statement of any intentional overage amount of a dietary ingredient;</p> <p>(f) A statement of theoretical yield of a manufactured dietary supplement expected at each point, step, or stage of the manufacturing process where control is needed to ensure the quality of the dietary supplement, and the expected yield when you finish manufacturing the dietary supplement, including the maximum and minimum percentages of theoretical yield beyond which a deviation investigation of a batch is necessary and material review is conducted and disposition decision is made;</p> <p>(g) A description of packaging and a representative label, or a cross-reference to the physical location of the actual or representative label;</p> <p>(h) Written instructions, including the following:</p> <ol style="list-style-type: none"> (1) Specifications for each point, step, or stage in the manufacturing process where control is necessary to ensure the quality of the dietary supplement and that the dietary supplement is packaged and labeled as specified in the master manufacturing record; (2) Procedures for sampling and a cross-reference to procedures for tests or examinations; (3) Specific actions necessary to perform and verify points, steps, or stages in the manufacturing process where control is necessary to ensure the quality of the dietary supplement and that the dietary supplement is packaged and labeled as specified in the master manufacturing record. <ol style="list-style-type: none"> (i) Such specific actions must include verifying the weight or measure of any component and verifying the addition of any component; and (ii) For manual operations, such specific actions must include: <ol style="list-style-type: none"> (A) One person weighing or measuring a component and another person verifying the weight or measure; and (B) One person adding the component and another person verifying the addition. (4) Special notations and precautions to be followed; and (5) Corrective action plans for use when a specification is not met. 		

Subpart I— Batch Production Record			
111.255	Batch Production Record		
	<p>(a) You must prepare a batch production record every time you manufacture a batch of a dietary supplement;</p> <p>(b) Your batch production record must include complete information relating to the production and control of each batch;</p> <p>(c) Your batch production record must accurately follow the appropriate master manufacturing record and you must perform each step in the production of the batch; and</p> <p>(d) You must make and keep batch production records in accordance with subpart P of this part.</p>		
111.260	Batch Record		
	<p>The batch production record must include the following:</p> <p>(a) The batch, lot, or control number:</p> <ol style="list-style-type: none"> (1) Of the finished batch of dietary supplement; and (2) That you assign in accordance with §111.415(f) for the following: <ol style="list-style-type: none"> (i) Each lot of packaged and labeled dietary supplement from the finished batch of dietary supplement; (ii) Each lot of dietary supplement, from the finished batch of dietary supplement, that you distribute to another person for packaging or labeling; <p>(b) The identity of equipment and processing lines used in producing the batch;</p> <p>(c) The date and time of the maintenance, cleaning, and sanitizing of the equipment and processing lines used in producing the batch, or a cross-reference to records, such as individual equipment logs, where this information is retained;</p> <p>(d) The unique identifier that you assigned to each component (or, when applicable, to a product that you receive from a supplier for packaging or labeling as a dietary supplement), packaging, and label used;</p> <p>(e) The identity and weight or measure of each component used;</p> <p>(f) A statement of the actual yield and a statement of the percentage of theoretical yield at appropriate phases of processing;</p> <p>(g) The actual results obtained during any monitoring operation;</p> <p>(h) The results of any testing or examination performed during the batch production, or a cross-reference to such results;</p> <p>(i) Documentation that the finished dietary supplement meets specifications established in accordance with §111.70(e) and (g);</p> <p>(j) Documentation, at the time of performance, of the manufacture of the batch, including:</p> <ol style="list-style-type: none"> (1) The date on which each step of the master manufacturing record was performed; and (2) The initials of the persons performing each step, including: <ol style="list-style-type: none"> (i) The initials of the person responsible for weighing or measuring each component used in the batch; (ii) The initials of the person responsible for verifying the weight or measure of each component used in the batch; 		

	<ul style="list-style-type: none"> (iii) The initials of the person responsible for adding the component to the batch; and (iv) The initials of the person responsible for verifying the addition of components to the batch; <p>(k) Documentation, at the time of performance, of packaging and labeling operations, including:</p> <ul style="list-style-type: none"> (1) The unique identifier that you assigned to packaging and labels used, the quantity of the packaging and labels used, and, when label reconciliation is required, reconciliation of any discrepancies between issuance and use of labels; (2) An actual or representative label, or a cross-reference to the physical location of the actual or representative label specified in the master manufacturing record; and (3) The results of any tests or examinations conducted on packaged and labeled dietary supplements (including repackaged or relabeled dietary supplements), or a cross-reference to the physical location of such results; <p>(l) Documentation at the time of performance that quality control personnel:</p> <ul style="list-style-type: none"> (1) Reviewed the batch production record, including: <ul style="list-style-type: none"> (i) Review of any monitoring operation required under subpart E of this part; and (ii) Review of the results of any tests and examinations, including tests and examinations conducted on components, in-process materials, finished batches of dietary supplements, and packaged and labeled dietary supplements; (2) Approved or rejected any reprocessing or repackaging; and (3) Approved and released, or rejected, the batch for distribution, including any reprocessed batch; and (4) Approved and released, or rejected, the packaged and labeled dietary supplement, including any repackaged or relabeled dietary supplement. <p>(m) Documentation at the time of performance of any required material review and disposition decision.</p> <p>(n) Documentation at the time of performance of any reprocessing.</p>		
Subpart J—Laboratory Operations			
111.303	Written Procedures		
	You must establish and follow written procedures for laboratory operations, including written procedures for the tests and examinations that you conduct to determine whether specifications are met.		
111.310	Laboratory Requirements		
	You must use adequate laboratory facilities to perform whatever testing and examinations are necessary to determine whether:		
	(a) Components that you use meet specifications;		
	(b) In-process specifications are met as specified in the master manufacturing record; and		
	(c) Dietary supplements that you manufacture meet specifications.		
111.315	§111.315 What are the requirements for laboratory control processes?		
	You must establish and follow laboratory control processes that are reviewed and approved by quality control personnel, including the following:		
	(a) Use of criteria for establishing appropriate specifications;		
	(b) Use of sampling plans for obtaining representative samples, in accordance with subpart E of this part, of:		
	(1) Components, packaging, and labels;		
	(2) In-process materials;		
	(3) Finished batches of dietary supplements;		
	(4) Product that you receive for packaging or labeling as a dietary supplement (and for distribution rather than for return to the supplier); and		
	(5) Packaged and labeled dietary supplements.		
	(c) Use of criteria for selecting appropriate examination and testing methods;		
	(d) Use of criteria for selecting standard reference materials used in performing tests and examinations; and		
	(e) Use of test methods and examinations in accordance with established criteria.		

111.320	Laboratory methods for testing and examination		
	(a) You must verify that the laboratory examination and testing methodologies are appropriate for their intended use. (b) You must identify and use an appropriate scientifically valid method for each established specification for which testing or examination is required to determine whether the specification is met.		
111.325	Records		
	(a) You must make and keep records required under this subpart J in accordance with subpart P of this part. (b) You must make and keep the following records: (1) Written procedures for laboratory operations, including written procedures for the tests and examinations that you conduct to determine whether specifications are met; (2) Documentation that laboratory methodology established in accordance with this subpart J is followed. (i) The person who conducts the testing and examination must document, at the time of performance, that laboratory methodology established in accordance with this subpart J is followed. (ii) The documentation for laboratory tests and examinations must include the results of the testing and examination.		
	Subpart K—Production and Process Control System: Requirements for Manufacturing Operations		
111.353	Written Procedures		
	You must establish and follow written procedures for manufacturing operations.		
111.355	Design requirements for manufacturing operations		
	You must design or select manufacturing processes to ensure that product specifications are consistently met.		
111.360	Sanitation		
	You must conduct all manufacturing operations in accordance with adequate sanitation principles.		
111.365	Precautions to prevent contamination		
	You must take all the necessary precautions during the manufacture of a dietary supplement to prevent contamination of components or dietary supplements. These precautions include: (a) Performing manufacturing operations under conditions and controls that protect against the potential for growth of microorganisms and the potential for contamination; (b) Washing or cleaning components that contain soil or other contaminants; (c) Using water that, at a minimum, complies with the applicable Federal, State, and local requirements and does not contaminate the dietary supplement when the water may become a component of the finished batch of dietary supplement; (d) Performing chemical, microbiological, or other testing, as necessary to prevent the use of contaminated components; (e) Sterilizing, pasteurizing, freezing, refrigerating, controlling hydrogen-ion concentration (pH), controlling humidity, controlling water activity (a_w), or using any other effective means to remove, destroy, or prevent the growth of microorganisms and prevent decomposition; (f) Holding components and dietary supplements that can support the rapid growth of microorganisms of public health significance in a manner that prevents the components and dietary supplements from becoming adulterated; (g) Identifying and holding any components or dietary supplements, for which a material review and disposition decision is required, in a manner that protects components or dietary supplements that are not under a material review against contamination and mix-ups with those that are under a material review;		

	<p>(h) Performing mechanical manufacturing steps (such as cutting, sorting, inspecting, shredding, drying, grinding, blending, and sifting) by any effective means to protect the dietary supplements against contamination, by, for example:</p> <ol style="list-style-type: none"> (1) Cleaning and sanitizing contact surfaces; (2) Using temperature controls; and (3) Using time controls. <p>(i) Using effective measures to protect against the inclusion of metal or other foreign material in components or dietary supplements, by, for example:</p> <ol style="list-style-type: none"> (1) Filters or strainers, (2) Traps, (3) Magnets, or (4) Electronic metal detectors. <p>(j) Segregating and identifying all containers for a specific batch of dietary supplements to identify their contents and, when necessary, the phase of manufacturing; and</p> <p>(k) Identifying all processing lines and major equipment used during manufacturing to indicate their contents, including the name of the dietary supplement and the specific batch or lot number and, when necessary, the phase of manufacturing.</p>		
111.370	Rejected dietary supplements		
	You must clearly identify, hold, and control under a quarantine system for appropriate disposition any dietary supplement that is rejected and unsuitable for use in manufacturing, packaging, or labeling operations.		
111.375	Records		
	(a) You must make and keep records required under this subpart K in accordance with subpart P of this part.		
	(b) You must make and keep records of the written procedures for manufacturing operations.		
	Subpart L—Packaging and Labeling Operations		
111.403	Written Procedures		
	You must establish and follow written procedures for packaging and labeling operations.		
111.410	Packaging & labeling		
	(a) You must take necessary actions to determine whether packaging for dietary supplements meets specifications so that the condition of the packaging will ensure the quality of your dietary supplements;		
	(b) You must control the issuance and use of packaging and labels and reconciliation of any issuance and use discrepancies. Label reconciliation is not required for cut or rolled labels if a 100-percent examination for correct labels is performed by appropriate electronic or electromechanical equipment during or after completion of finishing operations; and		
	(c) You must examine, before packaging and labeling operations, packaging and labels for each batch of dietary supplement to determine whether the packaging and labels conform to the master manufacturing record; and		
	(d) You must be able to determine the complete manufacturing history and control of the packaged and labeled dietary supplement through distribution.		

111.415	Filling, assembling, packaging, labeling, and related operations		
	<p>You must fill, assemble, package, label, and perform other related operations in a way that ensures the quality of the dietary supplement and that the dietary supplement is packaged and labeled as specified in the master manufacturing record. You must do this using any effective means, including the following:</p> <p>(a) Cleaning and sanitizing all filling and packaging equipment, utensils, and dietary supplement packaging, as appropriate;</p> <p>(b) Protecting manufactured dietary supplements from contamination, particularly airborne contamination;</p> <p>(c) Using sanitary handling procedures;</p> <p>(d) Establishing physical or spatial separation of packaging and label operations from operations on other components and dietary supplements to prevent mix-ups;</p> <p>(e) Identifying, by any effective means, filled dietary supplement containers that are set aside and held in unlabeled condition for future label operations, to prevent mix-ups;</p> <p>(f) Assigning a batch, lot, or control number to:</p> <ol style="list-style-type: none"> (1) Each lot of packaged and labeled dietary supplement from a finished batch of dietary supplement; and, (2) Each lot of dietary supplement, from a finished batch of dietary supplement, that you distribute to another person for packaging or labeling. <p>(g) Examining a representative sample of each batch of the packaged and labeled dietary supplement to determine whether the dietary supplement meets specifications established in accordance with §111.70(g); and</p> <p>(h) Suitably disposing of labels and packaging for dietary supplements that are obsolete or incorrect to ensure that they are not used in any future packaging and label operations.</p>		
111.420	Repackaging and relabeling		
	<p>(a) You may repack or relabel dietary supplements only after quality control personnel have approved such repackaging or relabeling.</p> <p>(b) You must examine a representative sample of each batch of repackaged or relabeled dietary supplements to determine whether the repackaged or relabeled dietary supplements meet all specifications established in accordance with §111.70(g).</p> <p>(c) Quality control personnel must approve or reject each batch of repackaged or relabeled dietary supplement prior to its release for distribution.</p>		
111.425	Packaged and labeled dietary supplement that is rejected for distribution		
	You must clearly identify, hold, and control under a quarantine system for appropriate disposition any packaged and labeled dietary supplement that is rejected for distribution.		
111.430	Records		
	<p>(a) You must make and keep records required under this subpart L in accordance with subpart P of this part.</p> <p>(b) You must make and keep records of the written procedures for packaging and labeling operations.</p>		
	Subpart M—Holding and Distributing		
111.453	Written Procedures		
	You must establish and follow written procedures for holding and distributing operations.		
111.455	Holding components, dietary supplements, packaging, and labels		
	<p>(a) You must hold components and dietary supplements under appropriate conditions of temperature, humidity, and light so that the identity, purity, strength, and composition of the components and dietary supplements are not affected.</p> <p>(b) You must hold packaging and labels under appropriate conditions so that the packaging and labels are not adversely affected.</p> <p>(c) You must hold components, dietary supplements, packaging, and labels under conditions that do not lead to the mix-up, contamination, or deterioration of components, dietary supplements, packaging, and labels.</p>		

111.460	Holding in-process material		
	(a) You must identify and hold in-process material under conditions that protect against mix-up, contamination, and deterioration. (b) You must hold in-process material under appropriate conditions of temperature, humidity, and light.		
111.465	Holding reserve samples of dietary supplements		
	(a) You must hold reserve samples of dietary supplements in a manner that protects against contamination and deterioration. This includes: (1) Holding the reserve samples under conditions consistent with product labels or, if no storage conditions are recommended on the label, under ordinary storage conditions; and (2) Using the same container-closure system in which the packaged and labeled dietary supplement is distributed, or if distributing dietary supplements to be packaged and labeled, using a container-closure system that provides essentially the same characteristics to protect against contamination or deterioration as the one in which you distribute the dietary supplement for packaging and labeling elsewhere. (b) You must retain reserve samples for 1 year past the shelf life date (if shelf life dating is used), or for 2 years from the date of distribution of the last batch of dietary supplements associated with the reserve samples, for use in appropriate investigations.		
111.470	Distributing dietary supplements		
	You must distribute dietary supplements under conditions that will protect the dietary supplements against contamination and deterioration.		
111.475	Records		
	(a) You must make and keep records required under this subpart M in accordance with subpart P of this part. (b) You must make and keep the following records: (1) Written procedures for holding and distributing operations; and (2) Records of product distribution.		
	Subpart N—Returned Dietary Supplements		
111.503	Written Procedures		
	You must establish and follow written procedures to fulfill the requirements of this subpart.		
111.510	Receipt of returned dietary supplement		
	You must identify and quarantine returned dietary supplements until quality control personnel conduct a material review and make a disposition decision.		
111.515	Destruction or disposal of returned dietary supplement		
	You must destroy, or otherwise suitably dispose of, any returned dietary supplement unless the outcome of a material review and disposition decision is that quality control personnel do the following: (a) Approve the salvage of the returned dietary supplement for redistribution or (b) Approve the returned dietary supplement for reprocessing.		
111.520	Salvaging of a returned dietary supplement		
	You may salvage a returned dietary supplement only if quality control personnel conduct a material review and make a disposition decision to allow the salvage.		
111.525	Returned dietary supplement that quality control personnel approve for reprocessing		
	(a) You must ensure that any returned dietary supplements that are reprocessed meet all product specifications established in accordance with §111.70(e); and (b) Quality control personnel must approve or reject the release for distribution of any returned dietary supplement that is reprocessed.		
111.530	Investigation of manufacturing processes and other batches?		
	If the reason for a dietary supplement being returned implicates other batches, you must conduct an investigation of your manufacturing processes and each of those other batches to determine compliance with specifications.		

111.535	Records		
	(a) You must make and keep records required under this subpart N in accordance with subpart P of this part. (b) You must make and keep the following records: (1) Written procedures for fulfilling the requirements of this subpart N. (2) Any material review and disposition decision on a returned dietary supplement; (3) The results of any testing or examination conducted to determine compliance with product specifications established under §111.70(e); and, (4) Documentation of the reevaluation by quality control personnel of any dietary supplement that is reprocessed and the determination by quality control personnel of whether the reprocessed dietary supplement meets product specifications established in accordance with §111.70(e).		
	Subpart O—Product Complaints		
	Written Procedures		
	You must establish and follow written procedures to fulfill the requirements of this subpart O.		
111.560	Review and investigation of a product complaint		
	(a) A qualified person must: (1) Review all product complaints to determine whether the product complaint involves a possible failure of a dietary supplement to meet any of its specifications, or any other requirements of this part 111, including those specifications and other requirements that, if not met, may result in a risk of illness or injury; and (2) Investigate any product complaint that involves a possible failure of a dietary supplement to meet any of its specifications, or any other requirements of this part, including those specifications and other requirements that, if not met, may result in a risk of illness or injury. (b) Quality control personnel must review and approve decisions about whether to investigate a product complaint and review and approve the findings and follow-up action of any investigation performed. (c) The review and investigation of the product complaint by a qualified person, and the review by quality control personnel about whether to investigate a product complaint, and the findings and follow-up action of any investigation performed, must extend to all relevant batches and records.		
111.570	Records		
	(a) You must make and keep the records required under this subpart O in accordance with subpart P of this part. (b) You must make and keep the following records: (1) Written procedures for fulfilling the requirements of this subpart, (2) A written record of every product complaint that is related to good manufacturing practice, (i) The person who performs the requirements of this subpart must document, at the time of performance, that the requirement was performed. (ii) The written record of the product complaint must include the following: (A) The name and description of the dietary supplement; (B) The batch, lot, or control number of the dietary supplement, if available; (C) The date the complaint was received and the name, address, or telephone number of the complainant, if available; (D) The nature of the complaint including, if known, how the product was used; (E) The reply to the complainant, if any; and (F) Findings of the investigation and follow-up action taken when an investigation is performed.		

	Subpart P—Records and Recordkeeping		
111.605	Records		
	(a) You must keep written records required by this part for 1 year past the shelf life date, if shelf life dating is used, or 2 years beyond the date of distribution of the last batch of dietary supplements associated with those records.		
	(b) Records must be kept as original records, as true copies (such as photocopies, microfilm, microfiche, or other accurate reproductions of the original records), or as electronic records.		
	(c) All electronic records must comply with part 11 of this chapter.		
111.610	Records that must be made available to FDA		
	(a) You must have all records required under this part, or copies of such records, readily available during the retention period for inspection and copying by FDA when requested.		
	(b) If you use reduction techniques, such as microfilming, you must make suitable reader and photocopying equipment readily available to FDA.		